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ABSTRACT

BIOTRANSFORMATION OF RESVERATROL AND ITS IMPLICATIONS IN
BIOLOGICAL ACTIVITIES IN THE COLON

SEPTEMBER 2018

FANG LI

B.S., NORTHWEST A&F UNIVERSITY, CHINA

Ph.D., UNIVERSITY OF MASSACHUSETTS, AMHERST, MA, USA

Directed by: Professor Hang Xiao
Resveratrol (RES) is a natural polyphenol compound with a wide range of healthpromoting activities, including protective effects against colon cancer and renal disease.
However, the premise of these benefits has been dampened since RES shows a poor oral
bioavailability due to its rapid and extensive biotransformation after oral consumption. The
paradox (low bioavailability but high bioactivity) warrants further investigations to
determine the contribution of RES metabolites to the health benefits associated with RES.
We identified 11 metabolites of RES in mice with high-resolution HPLC-MS/MS, then
quantified two major metabolites - dihydro-resveratrol (DHR) and lunularin (LUN). To
further understand the chemopreventative effects of RES metabolites in the kidney and
colon, the inhibitory effects of RES, DHR, LUN, and their combinations at the
vi

concentrations equivalent to those found in mouse tissues were determined in
corresponding cell models. Our results demonstrated that DHR and LUN exhibited much
stronger anti-inflammatory, anti-clonogenic and anti-proliferative effects than did RES at
physiologically relevant levels. Moreover, the combination of RES, DHR and LUN
produced the strongest inhibitory effects, while the contribution of RES was marginal.
DHR and LUN might be the main force that responsible for the chemopreventive effects
attributed to RES.

Accumulating evidence indicated that gut microbiota plays important roles in the
pathogenesis of colitis, and microbiota composition could be modulated by dietary
components. Therefore, ameliorating colitis-associated bacterial dysbiosis by dietary
components may be a unique strategy to improve gut health. Herein, we determined the
effects of resveratrol on gut microbiota and their implications in anti-colonic inflammation
in mice with colitis induced by dextran sodium sulfate (DSS). Our results reinforce the
protective effects of resveratrol in intestinal inflammation by alleviating the body weight
loss, reducing the disease activity index, attenuating tissue damage and down-regulating
the expression of pro-inflammatory cytokines such as IL-2, GM-CSF, IL-1β, IL-6 and
TNF-α in the colon of DSS-treated mice. Moreover, dietary resveratrol restored the
microbial richness and evenness in DSS-treated mice. Specifically, at the genus level
resveratrol effectively reduced the richness of Akkermansia, Dorea, Sutterella and
Bilophila and increased the abundance of Bifidobacterium in colitic mice. Furthermore, a

vii

Pearson’s correlation analysis indicated that resveratrol suppressed pro-inflammatory
cytokines were strongly correlated with gut microbiota composition. Overall, our results
suggested that dietary resveratrol attenuated inflammation perhaps by modulating the
microbial composition.

Fig. 1 Graphic abstract

The necessary role of gut microbiota in the biotransformation of RES was
evidenced by antibiotic treated mice. DHR, LUN, and their conjugates were completely
absent in the antibiotic treated mice. Moreover, we found that in colitic mice LUN and its
conjugates were extinguished, which may associate with the altered gut microbiota
composition and structure. Most interestingly, we found that RES metabolites at the
concentrations equivalent to that observed in the colonic tissues in colitic mice exhibited
significantly stronger chemopreventative effects than that observed in the healthy mice.

viii

These results suggested that absence of LUN may resulted in stronger biological activities
of RES. Overall, our results provided a solid scientific basis for understanding the
chemopreventive mechanisms of RES from the perspective of biotransformation and gut
microbiota and are of great value for future research on RES in prevention and treatment
of colonic diseases in humans.
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CHAPTER 1

INTRODUCTION

Resveratrol (trans-3, 5, 4’- trihydroxystilbene, RES), a stilbenoid, abundant in grapes,
wines, peanuts and mulberries. Its health beneficial bioactivities have been recognized and
studied widely. Accumulating evidence demonstrated the superior pharmacological
properties of RES such anti-cancer [1], anti-diabetes [2], anti-oxidant [3] and
cardiovascular protective effects [4]. However, RES is subjected to extensive
biotransformation mediated by drug-metabolizing enzymes, which may produce
metabolites with different bioactivities in comparison with the parent compound [5, 6].
Therefore, it is critical to establish the detailed information of the biotransformation and
tissue distribution of RES to better understand its mechanism of action. On the other hand,
metabolites may achieve higher concentrations than their parent compound at certain
tissues [7]. Therefore, the metabolites rather than the consumed components, may mainly
responsible for the biological effects at site of function. Regarding these concerns, one of
our current thesis aims is to identify and quantify metabolites of RES present in mouse
tissue, gastrointestinal tract (GIT) and biological fluids. And the potential chemopreventive
effects of RES metabolites were further investigated in corresponding cell-based models.

Over 1 million residents in the USA are estimated to be suffering from inflammatory
bowel disease (IBD) [8]. And one of the most important and devastating complications of
1

long-term IBD is colorectal cancer development [9]. Phytochemicals enriched diet have
been explored as a prophylactic tool to moderate the disease course [10]. Consistent results
showed that RES could down-regulated inflammatory biomarkers, reduced oxidative stress
and attenuated clinical symptoms in experimental murine colitis models [1, 3, 11].
However, the contribution of its metabolites in this process is not clear. Moreover, the
implication of gut microbiota dysbiosis on the pathogenesis of IBD has been highlighted
recently [12]. High accumulation of RES and its metabolites in cecum and colon suggesting
the dual interactions existing between gut microbiota and RES. Therefore, it is of great
significance to explore the mechanisms of anti-colitis effects of RES from the gut microbial
and metabolic perspectives.

The microbial biotransformation of dietary polyphenols, including ring fission,
reduction, demethylation, hydrolyzation glycosides, and dihydroxylation, has been well
described [13, 14]. On the one hand, significantly interindividual differences exist in gut
microbial composition, which may lead to different microbial transformation patterns of
polyphenols. As in the case of production of either equol or O-demethylangolensin and
dihydrodaidzein from daidzein [15]. Given the complex metabolism of other polyphenols
by gut microbiota, we speculated the pronounced interindividual different routes of
resveratrol biotransformation by the human gut microbiota. On the other hand, gut
microbiota composition could be dramatically altered in various diseases [16]. It is crucial
to systematically discuss the effects of altered gut microbiota on the biotransformation of

2

resveratrol and its important implications in biological activities of RES.

Our long-term goal is to the set up a database of bioavailability and bioactivities of
diet-based resveratrol administration in different diseases models and elucidate its
implication on various chemopreventive effects of RES. To reach this goal, our main
objective of this dissertation is to elucidate the biotransformation of resveratrol and its
implication on gut inflammation in DSS-induced colitis model. Our central hypothesis is
that resveratrol is extensively metabolized in vivo, and its metabolites are at least partially
responsible for the chemopreventive effects that attributed to RES. Dietary resveratrol will
restore the microbial dysbiosis in the colitic mice. In turn, its metabolic profile will be
changed in colitic mice. As a result, the biological activities of resveratrol will be different
in colitic mice.

We will test our central hypothesis and achieve our objective by completing the
following specific aims:

Specific Aim 1: Identification and quantification of resveratrol metabolites in mice
tissue after sustained oral consumption of RES. Mice will receive 0.5% (w/w) of RES for
four weeks. RES metabolites will be identified with Orbitrap HPLC-MS/MS in the urine
and fecal samples. The concentrations of RES metabolites will be quantified with HPLCMS in the organs/tissues, serum, bile, and gastrointestinal tract.

Specific Aim 2: Evaluate the chemopreventive effects of RES metabolites at
3

physiological levels in cell-based model. The in vitro anti-inflammatory efficacy of RES
metabolites will be determined in lipopolysaccharide (LPS)-stimulated RAW 264.7
macrophages. The in vitro growth inhibitory effects of RES metabolites on human renal
carcinoma cell lines and colon cancer cell lines will be determined by using cell viability
assay and colony formation assay.

Specific Aim 3: Evaluate the effects of dietary resveratrol on gut microbiota and its
implication on gut inflammation in DSS-induced colitic mice. Dextran sulfate sodium
(DSS)-induced colitis mice model will be used to assess the anti-inflammatory efficacy of
RES in vivo. Histological evaluation will be performed to assess the colon morphological
damage. ELISA assay will be used to determine the expression of inflammatory cytokines.
Gut microbiota composition will be analyzed with 16S-RNA based sequencing technique.

Specific Aim 4: Determine the role of gut microbiota in biotransformation of RES
and its implication in the anti-inflammation in the colon. Broad spectrum antibiotic will
be used to wash out the gut microbiota in mice. The metabolites of RES will be identified
and quantified with HPLC-MS in antibiotic treated mice. 300 mg of resveratrol capsules
will be assigned to eleven healthy volunteers every day for three days. The metabolites in
the urine samples will be quantified with HPLC-MS. We expect to observe pronounced
interindividual differences in RES biotransformation induced by gut microbiota. The
metabolites of RES in the cecum, colon, bile, liver, kidney, and serum in healthy mice and
DSS-treated mice will be analyzed and compared with HPLC-MS. We expect to observe
4

distinguished metabolism patterns of RES in healthy mice vs DSS-treated mice. The in
vitro anti-inflammatory efficacy of RES metabolites will be determined in
lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. The in vitro growth
inhibitory effects of RES metabolites on human colon cancer cell lines will be determined
by using cell viability assay.

5

CHAPTER 2

LITERATURE REVIEW

2.1 Introduction of biotransformation

2.1.1 Biotransformation

Since the chemopreventive agents in food are subjected to digestion, understanding
of metabolic fate of bioactive food components is crucial in elucidation the efficacy of
these compounds. Dietary bioactive compounds are regarded as xenobiotics by human
body. Therefore, as a self-defense, biotransformation will take actions to chemically
modify dietary bioactive compounds and eliminate them. Biotransformation can be defined
as production of chemical changes on compounds that are not their natural substrates by
using the biological systems [17]. In general, biotransformation reactions are divided into
two categories known as phase I and phase II metabolism. Phase I reactions including
oxidation, reduction and hydrolytic reaction, are mediated by enzymes such as CYP family
and amidases [18].
glucuronides,

In phase II reactions, small polar molecules, like sulfate and

conjugate

with

appropriate

functional

groups

of

substrates.

Glucuronosyltransferase, sulfotransferase and N-acetyltransferase are three most common
enzymes that mediate phase II metabolism [19]. Although the process of biotransformation
on one hand produces active metabolites from some dietary compounds [7]. On the other
hand, it reduces the plasma concentrations of dietary compounds [5]. Therefore,
6

elucidating the biotransformation of bioactive compounds is essential to better define the
bioavailability of dietary bioactive compounds and further evaluate their biological activity.

2.1.2 Implication of biotransformation in bioavailability

Bioavailability theoretically defined as the fraction of the administered dose that
reaches the general circulation unchanged [20]. It often characterized by the absorption,
tissue distribution, metabolism and elimination of the dietary bioactive compounds.

Different bioactive compounds show different rates of absorption. Biotransformation
can be a speed-limit step. Some of flavonoids naturally occurred as glycosides in plants,
which means glycoside moieties are attached to the flavonoids backbone. Glucosides need
to undergo deglycosylation prior to be absorbed [21], which is carried out by intracellular
cytoplasmic β-glucosidase [22]. For example, quercetin-3-O-rutinoside is deglycosylated
by rhamnosidases and β-glucosidase before absorbing by epithelial cells [23]. However,
recent evidence suggests that anthocyanins, e.g. cyanidin-3-glucoside, are rapidly and
efficiently absorbed in the small intestine intact without deglycosylation [24].

The biotransformation also plays an important role in the disposition of dietary
compounds, especially in the enteroenteric and enterohepatic circulation. Small intestine
and liver are the crucial tissues responsible for various biotransformation leading to
different conjugated forms of dietary bioactive compounds. However, kidney and other
tissue also involved in the metabolism of dietary bioactive compounds. Take anthocyanins
7

as an example (Fig. 2) [20]. After ingestion, only native anthocyanins are detected in
stomach. Once arriving at small intestine, extensive glucuronidation, sulphoation and
methylation of anthocyanins occurs. After absorption and intestinal biotransformation,
hepatic metabolism of anthocyanins takes place. Through enterohepatic recirculation, part
of the resultant anthocyanins can be recycled back to the small intestine through bile
excretion. As a result, anthocyanins metabolites (methylated and glucurono-conjugated
derivatives) are identified in various organs including bladder, prostate, testes, heart,
adipose tissue, liver, eyes, cerebellum and kidney as shown in Fig.2. The rest of
anthocyanins will pass from the small intestine to the large intestine where the gut
microbiota further bio-transform anthocyanins and their conjugates.

8

Fig. 2 Hypothetic pathways of anthocyanins absorption, distribution, metabolism and
excretion based on current information. Adopted from reference [17].

2.1.3 Implication of biotransformation on bioactivity

Biotransformation of dietary bioactive compounds affects properties such as mass,
charge and hydrophobicity, which may influence their ability to cross biological
membranes. It is also likely impacting their half-life in plasma and rates of excretion,
further influences their bioactivities. Quercetin is one of the most extensively studied
polyphenols. It has been shown that some conjugates of quercetin possess significant antioxidative, anti-inflammatory and anti-angiogenic properties [25, 26]. Conjugates derivate
from dietary polyphenols often have weakened bioactivities compared to the parent
compounds, and this seems to be the case for RES based on previous studies [6]. While,
Wu et al. demonstrated that metabolites of nobiletin showed much stronger anti-carcinoma
and anti-inflammatory effects than nobiletin itself [27]. Therefore, it is important to
determine the impacts of biotransformation on biological activities of dietary bioactive
compounds.

2.2 Inflammatory bowel disease

2.2.1 Introduction of inflammatory bowel disease

Inflammatory bowel disease (IBD), including relapsing-remitting inflammatory

9

disorders Crohn’s disease and ulcerative colitis, is a chronic inflammatory disease of
gastrointestinal tract [28]. Over 1 million residents in the USA are estimated to be suffering
from IBD [8]. One of the most important and devastating complications of long-term IBD
is colorectal cancer development [9]. The precise etiology of IBD remains unknown, the
most accepted hypothesis to date is that aberrant and continuing immune response against
the commensal gut microbiota in genetically susceptible hosts [28, 29]. Fig. 3 summarized

10

Fig. 3 Pathophysiology of inflammatory bowel disease. Adopted from reference [30].

The proposed pathophysiology of IBD. Tight junction is disrupted due to genetic or
environmental factors, which causes increased the change of uptake of commensal bacteria
and microbial products. Immune cells including macrophages, dendritic cells lead to
immune system activation and cytokines production. If acute inflammation cannot be
resolved by immune systems, chronic intestinal inflammation develops [30].

2.2.2 Preventive effects of phytochemicals on inflammatory bowel disease

IBD conduct a growing health concern due to increasing incidence worldwide. The
current notion on pathogenesis of IBD is the involvement of diet, gut microbiome and
epigenetics. Among these factors, diet plays an important role in modulating the gut
microbiota and influencing epigenetic changes [10]. Therefore, improving diet quality
could be applied as a prophylactic tool to moderate the disease course. Consequently, many
phytochemicals enriched diet have been explored as preventive treatments recently [31].
Previous studies indicated that high prevalence of IBD in northern Europe, United
Kingdom and North America may associated with their typical diet [32]. Paik et al
demonstrated that high-fat diet exacerbated IBD in Mdr1a-/- male mice [33]. While,
dietary polyphenols such as curcumin, quercetin, ellagic acid and resveratrol possess both
protective and therapeutic effects in the management of IBD via enhancing antioxidant
defense and suppressing inflammatory pathways [34]. Galvez et al. indicated that rutin can
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alleviate the inflammation and mucosa lesion by modulation the levels of internleukin-1
and tumor necrosis factor alpha [35]. Green tea polyphenols are widely studying for their
strong anti-oxidative effects. Several studies demonstrated the preventive effects of green
tea polyphenols on IBD [36].

2.3 Gut microbiota

2.3.1 Introduction of gut microbiota

The collection of bacteria, archaea, and eukarya living in the gastrointestinal tract
(GIT) is termed as the “gut microbiota” [37]. The number of bacterial cells inhabiting in
the GIT accounted ~10 times more than the number of human cells [37]. Gut microbiota
exerts a marked influence on the health of host by metabolizing nutrients, harvesting
energy, regulating immune system, and protecting intestinal epithelium [38]. Alteration
of gut microbiota composition (dysbiosis) is associated with the pathogenesis of many
disease.

Advanced sequencing techniques including 16S rRNA based bacterial sequencing and
whole-genome shotgun metagenomics allowed researches to survey the breath of the gut
microbiota. 16s rRNA is a popular approach, since 16S ribosomal RNA gene is present in
all bacteria and archaea, which allows species to be easily identified [39]. Whole-genome
shotgun metagenomics is more reliable than 16S rRNA based sequencing techniques due
to its higher resolution [39]. MetaHit and the Human Microbiome Project have provided
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the comprehensive data of human gut microbiota [40] 2172 species have been identified
from human samples, which are classified into 12 phyla, of which 93.5% belonged to
Proteobacteria, Firmicutes, Actinobacteria and Bacteroidetes [40].

Gut microbiota begin to develop since from birth. In the early stage, the microbiota is
in low diversity and dominated by Actinobacteria and Proteobacteria[41]. In the first year
of life, the microbial diversity increases, and the microbiota composition is distinct from
microbial profile in the adult [42]. By around 2.5 years old, the microbial diversity,
function, and composition are similar with adults [41]. Recently, cohort studies indicate
that gut microbial composition shifted, function compromised, and diversity decreased in
elder populations [43].

2.3.2 Diet shapes the gut microbiota

Diet can rapidly and reproducibly alter gut microbiota [44]. Food components (e.g.
fiber, polysaccharides, polyphenols), which are non-digestible to human enzymes, are
subjected to the intestinal microbial metabolism.

Dietary patterns, such as Western diets or plant-based diet, are strongly associated
with distinct gut microbiota compositions [44]. Previous studies observed that Clostridum
cluster XIVa, Bcteroides/Prevotella, Bacteroides thetaiotaomicron, and Faecalibacterum
prausnitzii were enriched in vegetarians compared with omnivores [45]. Moreover, another
comprehensive research reported that irrespective of age, the least microbial diversity was
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observed in adults of Americans vs Venezuela and Malawi [46].

Specific foods, such as whole grains, fruits, and vegetables, can partially get rid of the
metabolizing in the upper GIT, reach to the large intestine, and interact with gut microbiota.
Martinez et al. demonstrated that whole grains interventions led to an increased microbial
diversity, as well as a rise in the Firmicutes/Bacteroidetes ratio [47]. A placebo-controlled
crossover study revealed that wild blueberry drink enriched the gut microbial diverstity
and increased the amount of Bifidobacterium spp [48]. After consumption of red wine that
abundant with polyphenols, the relative counts of Bifidobacterium, Enterococcus, and
Eggerthella lenta were increased [49].

It is obvious that diet has an important influence on the structure and composition of
gut microbiota. Furthermore, the end products of bacterial metabolism, especially vitamins
and short-chain fatty acids (SCFA), are vital for human health.

2.3.3 Microbial biotransformation of dietary polyphenols

It has been estimated that only 5-10% of the total intake polyphenol can be absorbed
in the small intestine. The remaining 90-95% of intake polyphenol may accumulate in the
large intestinal lumen, where they are subjected to the enzymatic activities of gut microbial
community [50]. Currently, it is estimated that 500-1000 different microbial species inhabit
the gastrointestinal tract, reaching the highest concentrations in the colon (up to 1012 cells
per gram of feces) [50]. Thus, the encountering of gut microbiota and polyphenols can lead
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to the development of two-way mutual reactions. In one direction, polyphenols are biotransformed into their metabolites by gut microbiota that may results in the changed
biological activities. Bacterial metabolites are different from those that can be generated
by transferase enzymes because bacterial processes occur under anaerobic conditions and
are based mainly on reactions of reduction and/or hydrolysis.

Accordingly, luteolin is metabolized by colon microbiota (C. orbiscindens,
Enterococcus avium), breaking down its C-ring towards to phloretin chalcone, 3-(3,4dihydroxyphenyl) - propionic acid and 4-hydroxycinnamic acid, which are absorbed and
excreted by urine [51]. Ellagic acid is largely metabolized by the gut microbiota, giving
rise to urolithin A and its analog known as urolithin B [52]. However, it is noteworthy that
there is a large interindividual variation in colonic microbiota composition, which may
cause variations in the timing, quantity, and types of metabolites produced in large intestine.

In another way, polyphenols modulate the composition of gut microbial community
mostly by enhancing the probiotics and inhibiting the pathogenic bacteria. The interactions
between dietary bioactive compounds and gut microbiota may impact on human host health.
Several polyphenols have been recognized as potential prebiotics that can enrich the
beneficial bacteria in gut. It has been reported that grape seed extract resulted in the
dramatically increasing of Lactobacillus, Lachnospiraceae and Ruminococcaceae [53]. It
has been demonstrated that dietary supplemented-curcumin increased the abundance of
Lactobacillales, and decreased Coriobacterales order in AMO/Il10 model [54].
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Pterostilbene, an analog of resveratrol, modified intestinal bacteria composition toward to
a healthier microbial profile in obesity rats [55]. Overall, two-way, reciprocal interactions
of gut microbiota and phenolic compounds have an important impact on the bioavailability
of phenolic compounds and human health.

2.3.4 The role of gut microbiota in inflammatory bowel disease

The gut microbiota exerts a marked influence on the host during homeostasis and
disease. The possible implication of gut microbiota in the pathogenesis of IBD has been
highlighted recently. Multiple lines of evidence suggested the important role of gut
microbiota in the progress of IBD. Firstly, Metagenomic and 16S RNA based sequencing
studies demonstrated reduced diversity and altered composition of gut microbiota in
patients with IBD compared with healthy subjects [56-58]. Secondly, germ-free animals
were protected against colitis development in DSS-treated mice [12]. Thirdly, IL-10deficient mice, a murine model of IBD, did not develop colitis under germ-free conditions
[59]. All these results suggested that microbial factors might directly contribute to the
development of colonic inflammation and adverse metabolic consequences.

The gut microbiota has become an important target in the treatment of IBD, and
therapy has focused on correcting intestinal microbial imbalance. The gut microbiota,
including symbiotic, probiotic, and pathogenic microorganisms, plays an important role in
human health. Its balance can be destroyed by the introduction of invasive pathogens,

16

activation of immune cells, and production of pro-inflammatory cytokines [60]. Meantime,
interaction of dietary compounds and gut microbiota have been shown in great part to affect
the immune response and the inflammatory status [61]. Unravelling the complex
interactions underlying diet, IBD and gut microbiota will have implications for the
development of novel therapies.

2.4 Resveratrol

2.4.1 Introduction of resveratrol

Natural phytochemicals presenting in our diet have seen a wide range of acceptability
for the prevention and treatment of diseases. Resveratrol (3,4’,5-trihydroxystilbene) is a
polyphenolic compound, presenting itself in both trans- and cis- isomeric forms naturally.
It is found abundantly in red wine, grapes, peanuts and Japanese knotweed. The
concentrations of resveratrol in grapes varies from 0.16 to 3.54 μg/g depends the varieties
[62]. The concentrations of resveratrol in various types of wines ranged from 0.1 to 14.3
mg/L [62].

The use of resveratrol as a health-promoting dietary supplement is rapidly increasing
in market due to its numerous benefits including anti-oxidant, anti-cancer, anti-aging, antiinflammatory and the prevention of cardiovascular disease [63]. Furthermore, resveratrol
plays an effective role against various pathways such as, apoptosis, inflammation,
oxidative damage and angiogenesis [63]. The high efficiency of resveratrol might be owing
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to the three hydroxyl groups in its structure as shown in Fig. 4. Recent clinical trials proved
that resveratrol is well tolerated and pharmacologically safe at doses up to 5 g/day [64].

Fig. 4 Chemical structure of trans-resveratrol

2.4.2 Current studies on biotransformation of resveratrol

Low solubility of resveratrol in water and organic solvents (log P = 3.10), determined
by its chemical structure, impacts its absorption in vivo. Studies on metabolic conversion
and tissue distribution of RES are continuously undertaken [5, 65-70]. Fig. 5 summarized
the absorption and metabolism of resveratrol in vivo. the Studies convincingly
demonstrated that RES was highly absorbed but rapidly and extensively metabolized,
predominantly into glucuronides and sulfates derivatives, and only trace amount of RES
could be detected in the plasma [5, 65-68]. The maximum plasma peak concentration of
unmetabolized resveratrol was observed at 30-90 mins after oral consumption [5]. The
Appearance of the second peak at 6h after resveratrol intake indicated the enteric
recirculation and reabsorption of resveratrol [5].

Twelve conjugated metabolites of

resveratrol were identified, including resveratrol-3-O-sulfate, resveratrol-3-O-glucuronide,
resveratrol-4-O-glucuronide, resveratrol diglucuronide, resveratrol-sulfoglucuronide,
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resveratrol trisulfate, and resveratrol disulfate [66]. By using

14

C-labeled resveratrol,

dihydro-resveratrol (DHR) was firstly identified as a microbial metabolite of

Fig. 5 Absorption and metabolism of resveratrol. RSV stood for resveratrol, G-RSV stood
for glycoside resveratrol, CBG stood for cytosolic glucosidase, BG stood for betaglycosidases, UGT stood for uridine-5’-diphosphate-glucuronosyltransferase, SULT stood
for beta-glycosidase, UGT stood for uridine-5’-diphosphage-glucuronosyltransferase,
SULT stood for sulfotransferase, MRP2 stood for multidrug resistance protein, BCRP1
stood for breast cancer resistance protein 1. Figure is adopted from reference [30].
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resveratrol [5]. Later, the DHR derived metabolites were identified as well, such as DHR
diglucuronide, DHR sulfoglucuronide, DHR trisulfate, DHR-3-O-glucuronide, DHR
sulfate, and DHR disulfate [71], which together with its conjugates (sulfates and
glucuronides) accounted for as much as 50% of an oral RES dose [72]. With the in
analytical techniques lunularin (LUN) and 3,4’-dihydroxy-trans-stilbenes have been
recognized as microbial metabolites of RES in rats and humans [73-76]. Nevertheless, their
concentrations in tissues/plasma and their potential contribution to the pharmacological
efficacy of RES have not been probed yet.

2.4.3 Biological effects of resveratrol

Tons of researches suggests the low toxicity and high bioactivity of resveratrol. Many
studies have shown that resveratrol possess anti-oxidant, anti-cancer, anti-aging, antiinflammatory and the prevention of cardiovascular disease [63]. It is worth mentioning that
the effects of resveratrol heavily depending on its doses. At low concentrations (5 to 10
μM), resveratrol increased various cancer cells proliferation, while at higher concentrations
(higher than 15 μM) itinduced apoptosis [62]. It also has been reported that in
cardiovascular diseases, at low dose (5 to 10 μM) resveratrol functioned as anti-oxidant.
While at higher concentrations, it acts as prooxidant [77]. Consequently, resveratrol
possesses biphasic properties over low to high concentration, which is a critical point when
design it as a chemopreventative agent.
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Resveratrol has been reported to suppress proliferation of various tumor cells
including myeloid, breast, lung, liver, prostate, colon and stomach [78]. Moreover,
resveratrol induces apoptosis through various pathways: cell cycle arrest, silent
information regulator-mediated pathways, and caspase-8-dependent pathways [79].
Besides, resveratrol exhibits neuroprotective activity by enhancing glutathione and
decreasing malondialdehyde levels [80]. Lee et al, demonstrated that resveratrol
considerably attenuates dopamine-induced cell death in neuroblastoma cells by activating
the antiapoptotic factor Bcl-2 and inhibiting caspase-3 [81].

2.4.4 Biological effects of resveratrol metabolites

Nonetheless, these health benefits elicited by RES have been questioned, since it is
rapidly and extensively metabolized upon digestion, resulting in low plasma concentrations
[72]. This raises the impetus sparking the scientific inquiry that whether sufficient levels
of RES can be attained at the proposed function sites and whether RES metabolites might
contribute to the beneficial effects associated with the parent compound.

Therefore, researches diverted attentions to the chemopreventive effects of RESsulfates and RES-glucuronides [6, 82-85]. It has been reported that relative to RES, its
glucuronide and sulfate metabolites showed comparable or some degree of activities in
anti-oxidation [6], anti-inflammation [84, 85], and cytotoxicity against SW480, SW620
and SMMC-7721 cancer cell lines [6, 82]. Aires et al. reported that the mixture of RES-3-
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O-sulfate, RES-3-O-gucuronide, and RES-4’-O-glucuronide at the human plasma
concentrations exhibited synergistic inhibition effects on proliferation of colon cancer cells
[82]. Patel and Brown fed mice with RES-3-O-sulfate and RES-4’-O-sulfate proved that
sulfate metabolites served as an intracellular pool in the body from which RES could be
regenerated locally, and further demonstrated that RES mono-sulfates could inhibit the
growth of HT-29 cancer cells at clinically relevant concentrations [83]. Only limited
reports focused on DHR’s biological activities, especially at physiological levels. Lu et al.
[6] reported that DHR exhibited comparable activity compared to RES in inhibiting NO
production and liver cancer cells proliferation. Tang et al. accentuated that DHR showed
comparable inhibition effects with RES on pancreatic oxidative damage [86]. Along with
the discovering of new metabolites, it is important to reveal the contributions of resveratrol
metabolites on its biological activities.

2.4.5 Effects of resveratrol on inflammatory bowel diseases

Consistent results convinced the anti-inflammatory attribute of resveratrol. Very
recently a randomized, double-blind, placebo-controlled pilot study demonstrated that 6
weeks supplementation with 500 mg of resveratrol significantly reduced the levels of TNFα and hs-CRP in the plasma [87]. The mechanisms underlying anti-inflammation of
resveratrol are explained from following perspectives: down-regulation of inflammatory
MAPK, and NF-κB pathways, reduction of COX-2, modification the expression of
cytokines, diminish the leukocytes and alleviation of the clinical symptoms [88]. However,
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the involvement of gut microbiota in this progress has never been reported.
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CHAPTER 3

BIOTRANSFORMATION OF RESVERATROL IN THE GASTROINTESTINAL
TRACT DICTATES ITS BIOLOGICAL ACTIVITIES

3.1 Introduction

Resveratrol (trans-3, 5, 4’- trihydroxystilbene, RES), a phytochemical abundant in
grapes, wines, peanuts and mulberries, has attracted much scientific attentions because of
its potentially beneficial effects on numerous disorders, i.e. colon cancers [1],
cardiovascular disease [4], diabetes [2], neurodegenerative diseases [89], and renal
carcinoma [90]. Nonetheless, these health benefits elicited by RES have been questioned,
since it is rapidly and extensively metabolized upon digestion, resulting in low plasma
concentrations [72]. This raises the impetus sparking the scientific inquiry that whether
sufficient levels of RES can be attained at the proposed function sites and whether RES
metabolites might contribute to the beneficial effects associated with the parent compound.

Regarding these concerns, studies on metabolic conversion and tissue distribution of
RES are continuously undertaken [5, 65-70]. Studies convincingly demonstrated that RES
was highly absorbed but rapidly and extensively metabolized, predominantly into
glucuronides and sulfates derivatives, and only trace amount of RES could be detected in
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the plasma [5, 65-68]. Therefore, researches diverted attentions to the chemopreventive
effects of RES-sulfates and RES-glucuronides [6, 82-85]. It has been reported that relative
to RES, its glucuronide and sulfate metabolites showed comparable or some degree of
activities in anti-oxidation [6], anti-inflammation [84, 85], and cytotoxicity against SW480,
SW620 and SMMC-7721 cancer cell lines [6, 82]. Aires et al. reported that the mixture of
RES-3-O-sulfate, RES-3-O-gucuronide, and RES-4’-O-glucuronide at the human plasma
concentrations exhibited synergistic inhibition effects on proliferation of colon cancer cells
[82]. Patel and Brown fed mice with RES-3-O-sulfate and RES-4’-O-sulfate proved that
sulfate metabolites served as an intracellular pool in the body from which RES could be
regenerated locally, and further demonstrated that RES mono-sulfates could inhibit the
growth of HT-29 cancer cells at clinically relevant concentrations [83]. These findings
partially explained the RES paradox.

With the advances in analytical techniques, dihydro-resveratrol (DHR) was identified
as a microbial metabolite of RES in mice and humans [5, 65, 66, 91, 92], which together
with its conjugates (sulfates and glucuronides) accounted for as much as 50% of an oral
RES dose [72]. However, only limited reports focused on DHR’s biological activities,
especially at physiological levels. Lu et al. [6] reported that DHR exhibited comparable
activity compared to RES in inhibiting NO production and liver cancer cells proliferation.
Tang et al. accentuated that DHR showed comparable inhibition effects with RES on
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pancreatic oxidative damage [86]. Very recently, lunularin (LUN) and 3,4’-dihydroxytrans-stilbenes have been recognized as microbial metabolites of RES in rats and humans
[73-76]. Nevertheless, their concentrations in tissues/plasma and their potential
contribution to the pharmacological efficacy of RES have not been probed yet.

Regarding these research preceding, the purpose of this study was to identify and
quantify metabolites present in mouse tissues and biological fluid with Orbitrap Fusion
high-resolution HPLC-MS/MS after sustained oral consumption of RES. Based on the
concentrations observed in mouse kidney and colon, we further investigate the antiinflammatory, anti-clonogenic, and anti-proliferative efficacy of RES metabolites alone or
in combination in renal and colon cancer cells. Our findings provided important scientific
support to the notion that RES’s biological activities could be compensated by its
metabolites.

3.2 Materials and methods

3.2.1 Materials

RES (>99% purity) was purchased from Quality Phytochemicals (Edison, NJ, USA).
Pinostilbene (PIN) (>98% purity) and DHR (>98% purity) were obtained from Yuanye
Bio-Technology Co., Ltd (Shanghai, China). LUN (>98% purity) was purchased from
Aikon Biopharma LLC (Nanjing, China). Sulfatase (type H-1, from Helix pomatia,
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containing sulfatase and β-glucuronidase) was obtained from Sigma-Aldrich (St. Louis,
MO, USA). Acetonitrile (ACN), methanol (MeOH), acetic acid and ethyl acetate were
purchased from Fisher Scientific (Fairlawn, NJ, USA). All these solvents are HPLC grade.

3.2.2 Animas, diets and experimental design

The Institutional Animal Care and Use Committee, University of MassachusettsAmherst approved all animal experiments performed. Twenty male CD-1 mice (5-week
old) were obtained from Charles River Laboratory (Wilmington, MA, USA). After one
week of diet acclimation, ten mice were randomly chosen to receive standard AIN93G diet
containing 0.05% (w/w) RES, while the other ten remaining on standard diet. Urine and
feces were collected with metabolic cages. All mice were sacrificed with CO2 asphyxiation
after four weeks. Heart, liver, spleen, lung, kidney, brain, stomach, small intestine
(transversely cut equally into four parts), cecum, colon and bile were collected and stored
at -80°C for further analysis. Blood samples were centrifuged at 3 000g for 15 mins at 4°C
to collect serum.

3.2.3 Sample preparation

Serum, bile and urine samples were extracted according to Menet et al. [93]. Briefly,
aliquots of samples were vortex-mixed with ten volume of acidified (2.5% acetic acid)
ACN and stood at ice for 20 min to precipitate the protein. After centrifugation (14000 rpm,
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10min, 4°C), the supernatant was evaporated to dryness using a Speed Vac Concentrator
(Savant Thermo Fisher Scientific Inc., Agawam, MA, USA). Tissue samples were prepared
according to Juan et al. with modifications [67]. Briefly, aliquots of tissues were
homogenized with 10 volume of MeOH/water/acetic acid (80:20:2.5) solution using a Bead
Ruptor Homogenizer (Omni International, Kennesaw, GA, USA). The homogenates were
then centrifuged at 14000 rpm for 5 min. Specially for kidney samples, the homogenate
was sonicated for 20 min before centrifugation. The residues were extracted one more time
and combined methanolic layers were evaporated to dryness under vacuum. All sulfated
and glucuronide metabolites were measured by enzymatic hydrolysis of the processed
samples with β-glucuronidase and sulfatase as reference described [74]. The internal
standard PIN (5 μmol/L) was routinely used in all the samples. The dried extractions were
reconstituted in 50 μL 50% MeOH for further analysis.

3.2.4 Orbitrap Fusion high resolution HPLC-MS/MS and HPLC-MS analysis

Identification of RES metabolites was performed in an Ultimate 3000 RSLC HPLC
(Thermo Scientific, USA) coupled with Orbitrap Fusion High-Resolution Mass
Spectrometer (Thermo Scientific, Waltham, MA, USA). The metabolites were eluted with
a Zorbax SB-Aq C18 column (Agilent Technologies, Santa Clara, CA, USA) at flow rate
of 0.6 mL/min. Mobile phase A was 5% acetonitrile/water, mobile phase B was 100%
acetonitrile. Gradient elution started at 15% solvent B, linear gradient from 15 to 70%
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solvent B over 18 min, held at 70% B for 3 min, then followed by washing and
reconditioning the column. The Mass-spectra conditions were optimized at negative
electrospray ionization mode, as follows: ion spray voltage 3.5 kv, ion transfer tube
temperature 325°C, vaporizer temperature 275°C, sheath gas 15 Arb, aux gas 6 Arb,
Orbitrap resolution 120K, and collision energy 30%. Data acquisition and processing were
accomplished using Xcalibur V4.1 (Thermo Scientific).

The concentration of RES and its metabolites were quantified by using the Shimadzu
Model 2020 HPLC-MS (Shimadzu, Kyoto, Japan). The conditions of chromatography and
Mass-Spectra were same with Orbitrap Fusion HPLC-MS/MS, except the sample injection
volume was 20 μL rather than 5 μL. The data was processed with Labsolutions Software
(Shimadzu).

3.2.5 In vitro fermentation

Mouse fecal samples were collected from cecum and colon and placed into anaerobic
chamber (A35 anaerobic workstation, Whitley, USA) immediately. Aliquots of fecal
samples were suspended in gifu anaerobic broth (Hemedia). Small intestine digesta were
collected from RES-fed mice and incubated with fecal suspension under anoxic conditions
for 24 h. Digesta was defined as the complex aqueous suspensions of undigested matters
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and solubilized nutrients in GIT lumen [94]. 1 mL of samples were collected and extracted
with ethyl acetate for further HPLC-MS analysis.

3.2.6 Cell viability assay, colony formation assay, and nitric oxide assay

We adopted various cell models to investigate the multiple biological activities of RES
and its metabolites, including anti-proliferation of cancer cells, anti-inflammation, antioxidant and anti-colony formation. Mouse TLR-4 (mTLR-4) cell was purchased from
InvivoGen (San Diego, CA, USA). All other cells were purchased from American Type
Cell Collection (ATCC, Manassa, VA, USA). HT-29, HCT-116, A498 and 786-O were
applied to MTT and colony formation assays as described previously to explore the antiproliferatory effects [95-97]. Nitric oxide assay (anti-inflammation) were performed
according to Guo et al. in RAW264.7 macrophage model [95, 96]. mTLR-4 cells are
designed to specifically study that whether toll-like receptor 4 (TLR-4) mediated NF-κB
pathway involved. This experiment was conducted following manufacture’s HEK-Blue
protocol.

3.2.7 Statistical analysis

All data were expression as Mean ± SD. The statistical significance was assessed by
one-way ANOVA with post hoc Tukey HSD test. P value < 0.05 was considered as
statistically significant.
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3.3 Results and discussion

3.3.1 Identification of RES metabolites

To investigate the biological properties of resveratrol metabolites, the very first step
should be the identification of metabolites. By using high-resolution HPLC-MS/MS, RES
metabolites were characterized in urine and fecal samples. Blank urine and fecal samples
were injected to discard confounding ions not related to RES-derived metabolites (results
not shown). Eleven metabolites were detected in urine and fecal samples including two
microbial metabolites-DHR and LUN, three RES conjugates (RES-sulfate, RESglucuronide, and RES-sulfoglucuronide), four DHR conjugates (DHR-sulfate, DHRglucuronide, DHR-diglucuronides, and DHR-sulfate-glucuronide) and two LUN
conjugates (LUN-sulfate and LUN-glucuronide), as shown in Table 1 and Fig. 6. In
agreement with previous publications, the main RES metabolites were RES-sulfates, RESglucuronides, and RES-sulfoglucuronide as well as the microbiota-derived DHR and its
corresponding sulfate, glucuronide, diglucuronides, and sulfoglucuronide conjugates [5,
65-67, 91, 92]. LUN was identified as a microbial metabolite of RES in urine and fecal
samples recently [74, 76]. Importantly, for the first time, our results revealed that LUN
conjugates were important metabolites derived from resveratrol.
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Table 1 List of resveratrol metabolites identified with HPLC-MS/MS
Retention
#

Metabolites

time (min)

m/z [M-H]

MS/MS fragment

1

Resveratrol (RES)

13.67

227.0708

227.0702, 185.079, 143.0493

2

RES-sulfate

9.75/9.96

307.027

307.0269, 227.0702, 185.0595

3

RES-glucuronide

8.45/6.48

403.1029

403.1026, 227.0703, 113.0236, 175.0293

4

RES-sulfoglucuronide

6.86

483.0597

307.027, 227.0715, 113.0223

5

Dihydro-resveratrol

13.42

229.0865

229.0837, 123.0442, 81.0339

(DHR)
6

DHR-sulfate

9.65

309.0433

309.0424, 229.0395, 123.0443

7

DHR-glucuronide

8.55/8.60

405.1186

405.1161, 229.0865, 113.0235

8

DHR-diglucuronides

6.43

581.1506

405.1160, 229.0875, 175.0238, 113.0236

9

DHR-sulfoglucuronide

7.01

485.0754

485.0757,405.152, 309.0425, 113.0237

10

Lunularin (LUN)

17.14

213.0916

213.0912, 106.0415, 107.0494

11

LUN-sulfate

10.35/10.56

293.0484

293.0476, 213.0910, 79.9567, 107.0494

12

LUN-glucuronide

9.85

389.1236

389.1267, 213.0910, 113.0235

The spectra of metabolites were shown in Supplementary Fig. S1. RES, DHR and
LUN were fully identified by direct comparison with the authentic standards. The rest of
metabolites were tentatively identified regarding to their pseudo molecular ions and
daughter ions within 5ppm measurement error. For example, RES glucuronide showed a
[M-H]- ion at m/z 403.1029, which further fragmented to form a product ion of m/z
227.0703 that corresponded to RES itself after the loss of fragment at 113.0236 (Fig. S1).
This results was consistent with previous report [91]. The exact positions of these
conjugations in the resveratrol molecule were not established.
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Fig. 6 Chromatogram of eleven RES metabolites identified in urine and fecal samples after
sustained oral consumption of RES.

3.3.2 Distribution of RES and its metabolites in tissues and biological fluids

We further quantified the levels of RES and its metabolites in tissues/organs,
gastrointestinal tract (GIT) and biological fluids. Due to the paucity of available standards
for sulfate and glucuronide conjugates, their concentrations were assessed by enzymatic
hydrolysis as the whole, presenting as RES-conjugates, DHR-conjugates and LUNconjugates, respectively. We noticed that not even trace amount of unmetabolized RES was
detected in bile, liver, kidney and serum (Fig. 7A-7D), which implied that RES underwent
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extensive metabolism after oral consumption. More interestingly, DHR, LUN and their
conjugates were much more abundant than RES-conjugates (Fig. 7A-7D). RES and its
conjugates together were presented as RES-M and the same applied to DHR and LUN. As
shown in Fig. 7, DHR-M and LUN-M were 5.3- and 4.6- folds higher in bile, 1.2- and 4.8folds higher in serum, 10.3- and 3.4- folds higher in liver and 2.9- and 3.1-folds higher in
kidney than RES-M, respectively. Above results suggested that besides RES-sulfate, RESglucuronide and RES-sulfoglucuronide that were reported widely before, RES was more
profoundly metabolized into DHR, LUN and their conjugates after oral consumption.
Higher amounts of DHR-M than RES-M were reported before [72], while our current study
emphasized the high abundance of LUN-M in tissues for the first time. Considering the
absence of RES in tissues and limited bioactivity of RES conjugates, this was very useful
information since it indicated that DHR-M and LUN-M might play more important roles
than RES-M after oral administration of RES, due to their much greater abundance than
RES-M in tissues.

Moreover, high concentration of RES (179.1 μmol/L) and its conjugates (145.3 μmol/L)
were detected in urine (Fig. 7E). This result suggested that higher amount of RES-M was
excreted compared with DHR-M and LUN-M through urine, which further supported
previous results.
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Fig. 7 Distribution of RES, DHR, LUN and their conjugates in bile (A), kidney (B), liver
(C), serum (D) and urine (E). Data presented as mean ± SD (n=8).

3.3.3 Distribution of RES and its metabolites in GIT

For better understanding the metabolic pathways of RES after oral consumption, we
also examined the accumulation of RES metabolites in both the digesta and the
gastrointestinal (GI) tissues. Small intestine (SI) was equally cut into four segments
labelled as SI-1, 2, 3, and 4, referring to as the duodenum, jejunum, proximal ileum and
distal ileum in human.

Considerable amount of unmetabolized RES were detected in the stomach digesta, as
well as the occurrence of lesser extent of RES-conjugates, DHR, LUN, DHR-conjugates,
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and LUN-conjugates (Fig. 8A). Conjugates in stomach digesta could attribute to the
metabolizing ability of gastric cells [98]. The presence of DHR and its conjugates in the
stomach digesta has been reported before by Azorin-Ortuno et al [66], which was
tentatively explained by the presence of microbial groups in the stomach and SI involved
in the formation of DHR. This may also explain the appearance of LUN and its conjugates
in the stomach lumen. While, mice eat their feces, which contained large volumes of DHR
and LUN, could be another potential reason.
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Fig. 8 Levels of RES metabolites in gastrointestinal digesta and tissues. (A-C)
Concentration of RES, DHR, LUN and their corresponding conjugates in digesta. (D)
Relative abundance of RES metabolites in digesta. (E-G) Concentration of RES, DHR,
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LUN and their corresponding conjugates in GIT tissues. (H) Relative abundance of RES
metabolites in GIT tissues. (I) Concentration of RES, DHR, LUN and their conjugates
before and after anaerobic fermentation with mouse fecal bacteria. Data presented as mean
± SD (n=8).

Free-formed RES, DHR and LUN dominated (78.06%) in the stomach digesta. While
once the digesta arriving at the SI, the concentration of free-formed metabolites showed a
dramatic decline, meanwhile their conjugates significantly increased to 80.81% of total
RES metabolites (average of SI-1 to SI-4) (Fig. 8A-8D). The abundance of conjugates in
the SI digesta could due to several contributions together: catalyzed by transferase enzymes
that rich in SI enterocytes, an active efflux of conjugates to the lumen content, and biliary
secretion of the enterohepatic circulation [5, 66, 99]

However, when digesta reached the cecum and colon, conjugated metabolites
including those from DHR and LUN dramatically dropped down below 10.6% of the total
metabolites, while their corresponding parent compounds rocketed up (Fig. 8A-8D).
Similar situation have been reported in previous study [66]. We also noticed that the RESM dropped down from 47.97% of the total metabolites in the SI digesta (average) to 10.46%
in the large intestine inner content (average of the cecum and colon). While the abundance
of DHR-M and LUN-M increased at the meantime. (Fig. 8A-8D). Given the richness of
gut microbiota in the cecum and colon, we hypothesized that gut microbiota plays a role in
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the de-conjugation process and the production of DHR and LUN in the large intestine. To
examine our hypothesis, we incubated SI digesta, which was collected from RES-fed mice,
with mice-derived gut microbiota and determined the levels of free- and conjugatedmetabolites before and after the fermentation. We successfully observed that after 24h
anaerobic incubation, majority of the conjugates were converted back to their parent
compounds (Fig. 8I). We also found that the total amount of RES and its conjugates
decreased by 3.20 μmol/L after fermentation, while DHR-M increased by 1.12 μmol/L and
LUN-M increased by 0.16 μmol/L (Fig. 8I). Though this result did not strictly consistent
with our in vivo data, it still highly suggested the involvement of gut microbiota in the
biotransformation of RES to DHR and LUN. Bode et al. successfully identified Slackia
equolifaciens and Adlercreutzia equolifaciens as two DHR producers from human stools
[74]. The LUN producers, however, still had not been identified. The low increasedproportion of DHR-M and LUN-M might due to the limited in vitro fermentation
conditions so that the bacteria composition was different with that in vivo. The relative high
concentrations of DHR and LUN in the bile, could be considered because of the
reabsorption from the large intestine [100] (Fig. 7A).

The distribution of RES and its metabolites in the GI tissues had similar pattern with
GIT digesta, as shown in Fig. 8E-8H, excepting the lower concentrations and lesser
percentage of RES and its conjugates. The luxuriant enzymes in epithelial cells, such as
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cytochromes P450, UDP-glucuronosyltransferases, sulfotransferases, could be an
explanation of this observation [19]. Based on above discussion, the proposed metabolic
pathway of resveratrol was summarized in Fig. 9.

Fig. 9 Proposed metabolic pathway of RES. Solid arrows indicated metabolism conducted
by various transferases. Dotted arrows indicated the involvement of gut microbiota.

3.3.4 Metabolites of RES showed stronger chemopreventive effects than RES at
physiological concentrations

There are compelling evidences that RES exerts multiply chemopreventive properties
against various diseases. Nevertheless, these health benefits remained controversial due to
the low oral bioavailability and fast metabolism of RES [5, 72]. Consequently, the potential
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bioactivity of RES metabolites is an important question to solve to better understand RES’s
mechanisms of action. Conjugates derivate from dietary polyphenols often have weakened
bioactivities compared to the parent compounds, and this seems to be the case for RES
based on previous studies [6, 101]. Therefore, we focused on the chemopreventive effects
of two free-formed phase I metabolites (DHR and LUN) of RES in our study. RES
exhibited colon and renal protective effects and high levels of DHR and LUN were detected
in kidney and colon [1, 90]. Thus, the chemopreventative effects of DHR and LUN were
examined in renal and colonic cell lines. To establish the protective effects of RES and its
metabolites in a physiologically relevant manner, we deliberately used the concentrations
measured in tissues to determine their bioactivities.
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Fig. 10 Renal protective effects of DHR and LUN at renal relevant concentrations. Growth
inhibitory effects of DHR and LUN in 786-O (A) and A498 (B) renal carcinoma cells. DHR
and LUN potently inhibited colony formation of 786-O (C) and A498 (D) cells. Data
presented as mean ± SD (n=3). Different letters indicate statistical differences (P<0.05).

Regarding the zero concentration of RES in kidney, the renal protective effects of RES
inevitably drove attentions to its metabolites [90]. A498, a “classical” human renal
carcinoma cell line, is widely used as a model of clear cell renal cell carcinoma (ccRCC)
[102]. 786-O, with the phenotype of ccRCC, is primary cell line that most commonly used
in renal carcinoma focused researches [102]. These two cell lines were adopted to evaluate
the anti-proliferatory and anti-clonogenic effects of DHR and LUN at renal relevant
concentrations. Four levels of DHR, LUN and DHR+LUN were used at 0.5, 0.75, 1 and
1.5×. Concentration at 1× was equivalent to the concentrations (DHR: 14.3 nmol/g; LUN:
53.6 nmol/g) found in kidney tissues. Concentrations at 0.5, 0.75 and 1.5× were half, three
quarters and one and half times of the concentrations of RES metabolites at 1×. As shown
in Fig. 10, DHR and LUN inhibited the growth of both 786-O and A498 cells in a dosedependent manner. LUN showed stronger inhibitory effects than DHR in both 786-O and
A498 cells at all tested concentrations (P<0.05). LUN caused 15.6, 16.5, 18.2 and 25.4%
of inhibitions on 786-O cells at 0.5, 0.75, 1 and 1.5×, respectively. The combination of
DHR and LUN produced stronger inhibitory effects, i.e., at concentration of 1×, treatment
of DHR+LUN caused 23.2% death of 786-O cells. Similar results were also observed in
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A498 cells. A498 and 786-O cells were also subjected to anti-colony formation assay at
the 1× concentration. The formed-colonies were scanned and counted as shown in Fig. 10C,
7D. LUN significantly inhibited the clonogenic formation of A498 and 786-O cells by
43.38 and 48.44%, respectively (P<0.01). Combination of DHR and LUN exhibited
stronger inhibitory effects than LUN alone (P<0.05). As shown in Fig. 10C-10D,
DHR+LUN suppressed the colony formation by 54.15 and 62.03% in A498 and 786-O
cells, respectively. These results suggested that renal protective effects of RES might highly
relevant to its metabolites (DHR and LUN) in the kidney.

In order to establish the anti-colitis and anti-colon cancer effects of DHR and LUN in
a physiologically relevant manner, we determined their inhibitory effects on two widely
used human colon cancer cell lines (HCT-116 and HT-29) at the concentrations found in
the mouse colonic tissues. Treatment of 1× stood for concentrations measured in the
colonic tissue, that was, 4.3 μmol/L of RES, 42.8 μmol/L of DHR and 60.5 μmol/L of LUN.
DHR showed a tendency to suppress the proliferation of HCT-116 cells, although it did not
achieve a statistical significance. While, LUN profoundly and dose-dependently inhibited
the multiplication of HCT-116 cells since concentration of 0.75× compared to RES
(P<0.01). Markedly, DHR+LUN together showed stronger inhibitory effects than DHR
and LUN alone, i.e., at 1.0×，compared to 8.2 and 12.7% of inhibition induced by DHR
and LUN, DHR+LUN inhibited cell growth by 24.8% (P<0.05) (Fig. 11A).
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Interestingly, combination of all three compounds (RES+DHR+LUN) exerted the
strongest inhibition, however, it was not statistically greater than that produced by
combination of two metabolites (DHR+LUN). This finding further demonstrated the
meager contribution of RES itself to its in vivo protective effects against colon cancer. It is
noteworthy that at the concentration of 1.5×, DHR+LUN+RES showed no significant
inhibition on the growth of normal human colon CCD-18Co cells (Supplementary Fig. S2).
This result indicated that cytotoxic effects of RES, DHR and LUN were cancer cell specific.

In addition, HT-29 cells were subjected to different treatments at 1×. After 12 days of
incubation, the colonies formed were photographed and quantified as shown in Fig. 11B.
The numbers of colonies formed followed the order of RES > DHR > LUN > DHR+LUN >
RES+DHR+LUN. Compared to 5.0% of suppression caused by RES alone, treatments of
DHR, LUN, DHR+LUN and RES+DHR+LUN restricted the clonogenic survival of HT29 cells by 11.3, 35.2, 45.0 and 56.7%, respectively (P<0.05) (Fig. 11B). These results
indicated that RES metabolites might play more vital role in promoting the reproductive
death of colon cancer cells than RES itself in the colonic tissue after oral consumption of
RES.

Besides the anti-proliferative and anti-clonogenic effects, RES metabolites also
exerted stronger anti-inflammatory ability than RES at the colonic concentrations (Fig. 11C.
LPS-stimulated RAW 264.7 macrophages were used to determine the anti-inflammatory
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potency of DHR and LUN. LUN behaved a dose-dependent inhibition on LPS-induced NO
production (an important inflammatory mediator) by 14.2, 21.6, 28.3 and 38.2% at 0.5,
0.75, 1 and 1.5×, respectively (P<0.01). Overall, DHR did not produce a significant antiinflammatory ability, which was consistent with previous study [6]. The combined
treatments of DHR and LUN caused a significant decrease on production of NO compared
with LUN alone (P<0.01), i.e., 19.1, 26.8, 36.9 and 46.2% of NO inhibition throughout the
concentration range. Most interestingly, the combination of all three compounds (RES,
DHR and LUN) did not produce stronger inhibitory effects in comparison with the
combination of DHR and LUN (Fig. 11C).

To obtain further understanding of the anti-inflammatory signaling pathway, we
employed mTLR-4 cells to exam the involvement of NF-κB pathway. Stimulation of
mTLR-4 cells with a bacterial toxin LPS activated NF-κB and activator protein 1 (AP-1),
which induces the production of secreted embryonic alkaline phosphatase (SEAP). As
shown in Fig. 8D, single treatment of DHR and LUN at a concentration range of 0.75× to
1.5×, caused a significant dose-dependent inhibition on SEAP production compared to RES
alone (P<0.01). Furthermore, cotreatments with serial concentrations of DHR+LUN
resulted in suppression of SEAP production by 25.4, 40.6, 51.5 and 75.6% at 0.5, 0.75, 1
and 1.5×, respectively. The involvement of RES strengthened the inhibitory effects of
DHR+LUN on SEAP expression, but not statistically significant at lower concentrations
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(0.5 and 0.75×) (Fig. 11D). However, further analyses were required to clarify the specific
molecular mechanisms of anti-inflammatory effects of RES metabolites. Nonetheless, it
should be noted that RES exhibited stronger inhibitory effects on these cancer cell lines [6]
and NO production than DHR and LUN at the same concentration, however, this dose
range of RES is not achievable in our in vivo feeding study (Supplementary Fig. S3).
Overall, our results demonstrated that colonic metabolites of RES played more important
roles than RES itself in inhibiting cancer cell growth and inflammation.

Fig. 11 Chemopreventive effects of RES, DHR and LUN at colonic tissue levels. (A)
Growth inhibitory effects of RES, DHR and LUN on HCT-116 cancer cell line. (B) Anticlonogenic effects of RES, DHR and LUN on HT-29 cancer cell line. (C) Percentage of
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inhibition on NO production by RES, DHR, LUN and their combination in LPS-stimulated
RAW 264.7 cells. (D) Inhibitory effects of RES, DHR, LUN and their combination on LPSinduced SEAP production. Data presented as mean ± SD (n=3). Different letters indicate
statistical differences (P<0.05).

3.4 Conclusion

The present study for the first time systemically determined the biotransformation of
RES in mice, with focuses on its metabolic fate in the GIT. Our results demonstrated that
DHR, LUN and their corresponding conjugates were dominated metabolites of RES after
sustained oral consumption of RES, rather than RES-sulfates and RES-glucuronides. More
importantly, we found that DHR, LUN and their combination exerted much stronger
chemo-preventive and anti-inflammatory effects in the renal and colonic tissues, at their
concentrations achieved in these tissues, suggesting that DHR and LUN may greatly
contribute to the chemopreventive properties elicited by RES in the kidney and colon.
Overall, our findings provided a solid scientific basis for understanding the
chemopreventive mechanisms of RES from the perspective of biotransformation, and are
of great value for future research on RES in prevention and treatment of renal and colonic
diseases in humans
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CHAPTER 4
ANTI-INFLAMMATORY EFFECTS OF RESVERTROL ASSOCIATED WITH
THE ALTERATION OF GUT MICROBIOTA

4.1 Introduction

Inflammatory bowel disease (IBD), including relapsing-remitting inflammatory
disorders Crohn’s disease and ulcerative colitis, is a chronic inflammatory disease of
gastrointestinal tract [28]. Over 1 million residents in the USA are estimated to be suffering
from IBD [8]. One of the most important and devastating complications of long-term IBD
is colorectal cancer development [9]. The precise etiology of IBD remains unknown, the
most accepted hypothesis to date is that aberrant and continuing immune response against
the commensal gut microbiota in genetically susceptible hosts [28, 29]. The possible
implication of gut microbiota in the pathogenesis of IBD has been highlighted recently.
Multiple lines of evidence suggested the important role of gut microbiota in the progress
of IBD. Firstly, Metagenomic and 16S RNA based sequencing studies demonstrated
reduced diversity and altered composition of gut microbiota in patients with IBD compared
with healthy subjects [56-58]. Secondly, germ-free animals were protected against colitis
development in DSS-treated mice [12]. Thirdly, IL-10-deficient mice, a murine model of
IBD, did not develop colitis under germ-free conditions [59]. All these results suggested
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that microbial factors might directly contribute to the development of colonic inflammation
and adverse metabolic consequences.

The gut microbiota has become an important target in the treatment of IBD, and
therapy has focused on correcting intestinal microbial imbalance. The gut microbiota,
including symbiotic, probiotic, and pathogenic microorganisms, plays an important role in
human health. Its balance can be destroyed by the introduction of invasive pathogens,
activation of immune cells, and production of pro-inflammatory cytokines [60]. Diet has
an influence in shaping the development and composition of the gut microbiota and many
phytochemicals enriched diet have been explored as preventive treatments of IBD recently
[31].

Resveratrol (3,5,4’-trihydroxy-trans-stilbene) is a natural polyphenol abundant in
grapes, wines and peanuts. Consistent results showed that resveratrol could down-regulated
inflammatory biomarkers, reduced oxidative stress and attenuated clinical symptoms in
experimental murine colitis models [1, 3, 103]. A recent human study claimed that 6-weeks
supplementation of resveratrol could improve clinical colitis [87]. Moreover, high
accumulation of resveratrol in the gastrointestinal tract (65.1%) was reported, suggesting
it could arrive intact at the colon, where it may interact with micro flora [71]. In the view
of direct contact and dual interaction existing between resveratrol and gut microbiota,
possible composition modifications in gut microbiota might be expected as a result of
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consumption of resveratrol, which ultimately contribute to its anti-inflammation property.

Given the complex relationship among diet, IBD and gut microbiota. The purpose of
this study was to elucidate whether supplementation of trans-resveratrol could counteract
gut microbiota dysbiosis produced by DSS-induced colitis and whether these changes
might be correlated with anti-colitis effects of resveratrol.

4.2 Materials and Methods

4.2.1 Animals and experimental design

Institutional Animal Care and Use Committee of University of Massachusetts
Amherst approved the protocol for the animal experiment. 40 male wild-type CD-1 mice
(6-8 weeks old) were obtained from Charles River Laboratories (Wilmington, MA, USA).
Animals were randomly assigned to four groups and housed in groups of five mice per
cage in a temperature-controlled environment (22±2 °C) with 65 % relative humidity and
fixed 12 h light/dark cycle. After one-week diet acclimation, four groups were distributed
as follows: the control group (RES-, DSS-; n=10), which was fed with standard chow
(AIN93G diet); the resveratrol group (RES+, DSS-; n=10), which was fed with the standard
diet supplemented with 0.025% (w/w) resveratrol (>99% purity) (Quality Phytochemicals,
NJ, USA); the DSS group (RES-, DSS+; n=10), which received the standard diet and 1.5%
DSS water (wt/v, dextran sulfate sodium salt) (International Lab, Chicago, IL, USA); and
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the resveratrol-DSS group (DSS+, RES+; n=10), which received resveratrol (0.025% w/w)
supplemented diet and 1.5 % DSS drinking water (wt/v). 1.5% DSS was administered in
the drinking tap sterilized water ad libitum for 4 days followed by 7 days of pure water for
recovery, and this cycle was repeated four times. Body weight and disease activity index
(DAI) were monitored at every last day of recovery cycles and DSS cycles. At the end of
the fourth cycle of DSS treatment, all mice were sacrificed with CO2 asphyxiation. The
liver, spleen and kidney were removed and weighted. After measurement of weight and
length, the entire colon was cut into two pieces longitudinally. Half of the colon was fixed
in 10% buffered formalin (pH=7.4) for further histopathological analysis. The other half
of the colon was stored at -80°C for ELISA analysis. The feces collected from colon were
stored at -80°C for further sequencing analysis.

4.2.2 DAI and histological assessment

DAI was determined by scoring extent of rectal bleeding (Score: 0, none; 1, hemoccult
positive; 2, blood; 3, gross bleeding), stool consistency (Score: 0, normal; 1, soft but form;
2, soft; 3, diarrhea) and weight loss (Score: 0, none; 1, 1~5%; 2, 5~10%; 3, 10~20%;
4, >20%) [104]. The final macroscopic score for each animal is the sum of each individual
score.

Formalin fixed colon tissues was processed for paraffin embedding, sectioning (5 μm),

51

and haematoxylin and eosin (H&E) staining as previously described [7, 105, 106]. Three
parameters were graded: surface epithelial loss, crypt destruction and inflammatory cell
infiltration into the mucosa based on the established criteria [107]. A score of 0-4 was
assigned to each parameter (maximum macroscopic score = 12).

4.2.3 Enzyme-linked immunosorbent assay (ELISA)

Colonic mucosa was scraped and homogenized in MSD Tris lysis buffer (Meso Scale
Discovery, Rockville, MD, USA) contained with 1% protease inhibitor cocktail (Boston
Bioproducts, Ashland, MA, USA). Supernatants were collected by centrifuging at 14000
rpm for 20min at 4°C, then loaded in sandwich enzyme-linked immunosorbent assay kits
(Meso Scale Discovery, Rockville, MD, USA) to determine the concentrations of cytokines
according to the manufacturer’s instructions.

4.2.4 16S rRNA analysis and Illumina Mi-Seq sequencing

Fresh fecal samples were collected from colon and immediately frozen at −80°C for
future analyses. Bacterial DNA was extracted from feces by using the PowerFecal DNA
isolation kit (MoBio Laboratories, Inc., Carlsbad, CA), following supplier’s protocols. The
DNA was quantified by the NanoDrop spectrophotometer (Thermo Scientific, Waltham,
MA, USA) and normalized to 20 ng/μL. 16s rRNA genes were amplified with PCR by
using

Forward
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primer

5'TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG
and

Reverse

Primer

=

5’GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
ATCC as described by Klindworth et al. [108]. Amplicons of interest was verified by gel
electrophoresis. If required, low yields were further amplified. PCR products were then
purified with AMPure XP beads (Beckman Coulter, Danvers MA, US) to remove primer
dimers and other small mispriming products. Dual indices and Illumina sequencing
adapters were attached by PCR using the Nextera XT Index Kit (Illumina, San Diego, CA,
US). The quantity and size of PCR products were determined and verified by using Qubit
dsDNA BR Assay kit (Life technology, Carlsbad, CA, US) and DNA analysis ScreenTape
Assay on Tape Station 2200 (Agilent Technologies, Santa Clara, CA, US). Final PCR
products were pooled in equimolar concentration and denatured by NaOH. After
combining the amplicon library and PhiX control, the samples were loaded onto the 600cycle MiSeq Reagent kit v3 cartridge and sequenced on an Illumina MiSeq platform
(Illumina Inc, San Diego, CA, USA).

4.2.5 Statistical analysis

Raw Illumina Miseq sequence data were processed with Quantitative Insights Into
Microbial Ecology (QIIME) software pipeline v1.9.1[109]. Generated operational
taxonomic units (OTUs) were further subjected to alpha- and beta-diversity and principal
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coordinate analysis (PCoA) analyses using QIIME. Cladogram and Linear discriminant
analysis (LDA) characterized by LEfSe tool [110]. The LEfSe analysis was performed
using an alpha value of 0.01 for both the factorial Kruskal-Wallis rank sum test and
pairwise Wilcoxon test and a threshold of 2.0 for the LDA. The approach used was an allagainst-all multi-class analysis. Correlation analyses were performed with SPSS 17.0
software (Chicago, IL, USA). Data were presented as the mean ± standard error of the
mean (SEM). The statistical significance of differences among groups was performed using
one-way ANOVA followed by Tukey-Kramer multiple comparison post hoc analysis. The
differences between groups were considered significant at P< 0.05.

4.3 Results

4.3.1 Dietary resveratrol attenuated colitis symptoms

Cyclic administration of DSS in drinking water resulted in the establishment of
chronic colitis and the development of colorectal dysplasia in mice [111]. Body weight was
monitored at the end of every DSS and recovery cycles, as an indicator of colitis severity.
Lower percentage of body weight gain was observed since the end of the first DSS cycle.
With increased DSS-treatment cycles, the percentage of body weight gain in DSS group
was getting lower and lower than control group and statistically significant at the fourth
DSS cycle (P < 0.05), while dietary resveratrol significantly counteracted this trend in DSS-
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treated mice (Fig. 12A). The final body weight was 48.98 ± 5.06 g for control group, and
significantly decreased to 36.92 ± 3.05 g for DSS group (P < 0.01). Whilst, dietary
resveratrol supplementation ameliorated the body weight loss by elevating the final body
weight to 44.78 ± 1.61 g in DSS-treated mice (P < 0.01) (Fig. 12B). DAI exhibits features
of fecal consistency, haematochezia and body weight loss, and is used to evaluate
inflammation severity in mice with colitis [104]. The DAI score was as high as 7.9 ± 1.9
in DSS treated group, whereas it was markedly attenuated by 1.8-fold with resveratrol
treatment (P< 0.05) (Fig. 12C). Colon weight/length ratio is another index that correlated
with the progression of colorectal inflammation. As shown in Fig.12D, compared to the
DSS group, dietary supplement of resveratrol rescued the inflammation-associated
elevation of colon weight/length ratio (P < 0.05). Furthermore, remarkable increased in the
ratio of spleen to final body weight were observed in DSS-treated mice compared with
control mice. Dietary resveratrol significantly decreased this spleen to final body weight
ratio to control level (P < 0.05) (Fig. 12E). These results suggested that dietary resveratrol
offered protective effects against DSS-induced colitis.
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Fig. 12 Dietary resveratrol attenuated colitis symptoms. (A) Percentage of body weight
gain during entire experiment; (B) Final body weight; (C) Disease activity index (DAI);
(D) Colon weight to colon length ratio; (E) Spleen weight to body weight ratio. Data are
mean ± SD (n=10). Significant differences are indicated: *, P<0.05, **, P<0.01.

4.3.2 Dietary resveratrol suppressed DSS-induced colitis by improving colonic tissue
damage and reducing the colonic levels of pro-inflammatory cytokines

Histological H&E staining of the colonic segments from DSS group showed severe
inflammatory lesions, supported by the significant distortion of crypts structure, infiltration
of inflammatory cell, edema of submucosa, and formation of dysplasia (Fig. 13A).
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Resveratrol supplementation significantly mitigated morphological alteration associated
with DSS treatment, thus protected colonic structure. In majority of areas, the epithelium
and mucosal architecture remained intact (Fig. 13A). Damage of colonic mucosa assessed
by overall histological score was 1.7-fold higher (P < 0.01) in the DSS group compared to
the resveratrol-DSS group (Fig. 13B).

Cytokines play a vital role in the pathogenesis of IBD. The imbalance between antiinflammatory and pro-inflammatory cytokines results in colonic diseases [112]. The
expression levels of granulocyte-macrophage colony-stimulating factor (GM-CSF),
interferon gamma (IFN-γ), Interleukin 10 (IL-10), Interleukin 2 (IL-2), Interleukin 1 beta
(IL-1β), Interleukin 6 (IL-6), keratinocyte chemoattractant/human growth-regulated
oncogene (KC/GRO), and tumor necrosis factor alpha (TNF-α) in colon mucosa were
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Fig. 13 Dietary resveratrol improved tissue damage and suppressed the overexpression of
inflammatory cytokines. (A) Representative colon tissue images of H&E-stained
colorectum sections (60X magnification); (B) Histology score; (C) Concentration of
inflammatory cytokines (GM-CFS, IFN-γ, IL-10, IL-2, IL-1β, IL-6, KC/GRO, and TNF-α)
in colonic mucosa. Data are mean ± SD (n= 6-8). Significant differences are indicated: *,
P<0.05; **, P<0.01.

increased to 5.2, 8.7, 2.0, 2.1, 10.0, 47.9, 10.9 and 7.0-fold over control levels, respectively,
in mice consumed 1.5% DSS drinking water (P < 0.05) (Fig. 13C). While consumption of
resveratrol markedly reduced their colonic expression by 44.2%， 48.5%， 43.2%, 46.8%，
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58.0%, 79.9%，48.5%, and 46.5%, respectively (P < 0.05) (Fig. 13C). Taken pathological
changes together, these results suggested the effective capacity of dietary resveratrol to
mitigate the severity of DSS-induced colitis by down-regulating the level of colonic proinflammatory cytokines.

4.3.3 Resveratrol partially rescued gut microbiota dysbiosis induced by DSS

Ilumina Mi-Seq sequencing of the 16S rRNA gene of fecal samples analyzed effects
of dietary resveratrol on gut microbiota structure and composition. Expressive changes
observed in the microbial ecology (Fig. 14). The terms of OTUs mean a cluster of related
(no less than 97% similarity) 16S rRNA sequences [113]. Numbers of OTUs, Shannon
diversity, Chao1, and phylogenetic distance (PD) whole tree are common indexes of αdiversity that indicate the depth of sequence coverage and community diversity within
samples [114]. As shown in Fig. 14A, dietary resveratrol significantly enriched the
bacterial diversity versus control group (P < 0.05), while DSS treatment prevented the
enrichment of microbiota caused by resveratrol (P < 0.05). Bacterial α-diversity was
marginally decreased in DSS-treated group compared with control group (P < 0.05) for
Numbers of OTUs), suggesting similar richness and evenness of community species
between these two groups (Fig. 14A). There were no significant differences of PD whole
tree among groups (Data not shown). Additionally, the structure of fecal microbiota was
further assessed by β-diversity, which generated based on the number of shared species
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between samples [27]. The weighted β-diversity (weighted UniFrac distances) analysis
suggested that DSS treatment dramatically shifted the fecal microbiota, supported by a
significant distance between control and DSS group (P = 0.009). While dietary resveratrol
dragged the plot back toward the control group and clearly distinguished with DSS group
(P = 0.008) (Fig. 14B), which implied that administration of resveratrol partially blunted
the dysbiosis caused by DSS. The presence of overlapping clusters between control and
resveratrol group illustrated the relative similarity of microbial profiles between these two
groups (Fig. 14B).

To profile the specific changes in the gut microbiota, we analyzed the relative
abundance of the predominant taxa identified from sequencing in all groups (Fig 14C-14F).
At the phylum level, there were no significant differences existed between control and
resveratrol group, except the up-regulation of Bacteroidetes in resveratrol group (P < 0.05)
(Fig. 14C-14E). This result was consistent with previous studies [115]. DSS treatment
significantly altered the bacterial structure by contributing the expansion of
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Verrucomicrobia and Proteobacteria and contraction of Actinobacteria and Firmcutes
versus control group (P < 0.05). However, consumption of resveratrol partially reversed
this dysbiosis by down-regulation the abundance of Verrucomicrobia from 29.7% to 20.8%
and Proteobacteria from 11.7% to 3.6% and up-regulation the abundance of Actinobacteria
from 1.2% to 6.9% (P < 0.05) (Fig. 14C-14E). At the genus level, the aberrant dominance
of Akkermansia (29.7% of sequences) were observed in DSS group, while it accounted no
more than 1.5% of whole composition in control and resveratrol group. In contrast, dietary
resveratrol significantly inhibited the excessively proliferation of Akkermansia (18.8%) in
DSS-treated mice (P < 0.05) (Fig. 14D-14F). Similarly, resveratrol supplementation
significantly inhibited the abnormal bloom of Boliphila, Sutterella and Dorea in DSS-fed
mice (P < 0.05) (Fig. 14D-14F). We also noticed that the consumption of resveratrol
significantly lifted the Bifidobacterium counts to 8.0% compared to 5.7% in control group
(P < 0.05). Meanwhile, its relative abundance dropped down to 1.2% in DSS group and
recovered to control level (6.7%) in DSS-resveratrol group (P < 0.05) (Fig. 14D-14F).
These results indicated that resveratrol treatment restored the gut microbiota communities
to compositions resembling those of the healthy control group.
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Fig. 14 Dietary resveratrol partially rescued gut microbiota dysbiosis in colitic mice. (A)
α-diversity of gut microbiota with different indices - numbers of OTUs, Shannon index and
Chao1 (P < 0.05); (B) PCoA plots based on weighted UniFrac distances representing
changes of gut microbial community among different groups (P<0.01); (C) Gut microbiota
composition at the phylum level; (E) Cladogram generated from default LEfSe analysis
showing the most differentially abundant taxa enriched in microbiota among different
groups (α < 0.1 for factorial Kruskal-Wallis test); (F) LDA scores of the differentially
abundant taxa (with LDA score >2 and and significance of α < 0.1, determined by KruskalWallis test); (G) Relative abundance of gut microbiota at the genus level (P < 0.05). Data
are mean ± SD (n=5). Different letters represent statistically differences.

4.3.4 Alterations in gut microbiota correlated with aberrant cytokine expression
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To determine whether alteration of the gut microbiota could be associated with
abnormal expression of inflammatory cytokines, we examined the correlation between gut
microbiota phylotypes and colonic cytokines (Fig. 15). As a result, consistent positive
linkages were detected between potentially pathogenic organisms enriched in DSS group
and pro-inflammatory cytokines. For example, at the phylum level Proteobacteria were
significantly positively correlated with GM-CSF, IL-1β, IL-2, IL-6, KC/GRO and TNF-α
(p < 0.05). Similarly, the abundance of genera Boliphila and Sutterella who belong to
Proteobacteria positively correlated with pro-inflammatory cytokines, including IL-1β,
IL-6 and IFN-γ (p < 0.05). We also observed that health promoting gut microbiota were
negatively correlated with pro-inflammatory cytokines and positively correlated with antiinflammatory cytokines. Specifically, Bifidobacterium was highly negatively correlated
with IL-1β, IL-6, KC/GRO and TNF-α (P < 0.05), and positively correlated with IL-4.
Same to Lactobacillus, negative correlations were observed with pro-inflammatory
cytokines (GM-CSF, IFN-γ, IL-1β, KC/GRO, and TNF-α) (P < 0.05). These data suggested
that mutation in bacterial composition might influence changes in the expression of
inflammatory cytokines in colon.
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Fig. 15 Heatmap of correlation between gut microbiota and inflammatory cytokines.
Positive correlation is in red. Negative corelation is in black. Significant differences are
indicated: *, P<0.05; * *, P<0.01.

4.4 Discussion
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IBD conduct a growing health concern due to increasing incidence worldwide. The
current notion on pathogenesis of IBD is the involvement of diet, gut microbiome and
epigentics. Among these factors, diet plays an important role in modulating the gut
microbiota and influencing epigenetic changes [10]. Therefore, improving diet quality
could be applied as a prophylactic tool to moderate the disease course. Consequently, many
phytochemicals enriched diet have been explored as preventive treatments recently [31].
The protective effects of resveratrol against acute or chronic colitis in different models
were demonstrated in previous studies [3, 103, 116, 117]. However, the mechanism of antiinflammation effects of resveratrol, especially the role of gut microbiota has not been
illustrated yet. DSS (a chemical agent) induces colitis by disrupting the epithelial barrier
and increasing colonic permeability, which is critical for the IBD onset. This impairment
of gut barrier allows for gut-derived bacteria, disrupts balance of probiotics and pathogens,
and leads to increased interactions between microbiota and immune system [118]. A
complex interplay exists among diet, IBD, intestinal epithelium and microbial communities
in the maintenance of gastrointestinal homeostasis. Therefore, it is of great significance to
further explore the mechanisms of anti-colitis effects of resveratrol from the gut microbial
perspective. One previous research studied the impacts of dietary resveratrol on several gut
bacteria in acute colitis model by traditional counting method [117]. Now 16S rRNA-based
sequencing allows fully identifying and profiling the structure and composition of gut
microbiota in our study.
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In this research, we investigated the interplay between dietary resveratrol, gut
microbiota and chronic colitis in the in vivo model. The resveratrol dose assayed is
equivalent to 2 mg/kg/day in humans approximately, which is conveniently achievable
through dietary supplementation. We found that consumed achievable dose of resveratrol
significantly inhibited colitis by alleviating the loss of body weight, DAI, colon shortening,
tissue injury and inflammatory cytokine changes induced by DSS treatment. These results
agree with former researches [3, 116, 117], which suggested that resveratrol exerts an antiinflammatory action in DSS-induced colitis and is capable of preventing DSS induced
colitis.

Cytokines play a crucial role in driving and mediating intestinal inflammation. The
severity of IBD is associated with up-regulation of pro-inflammatory cytokines and downregulation of anti-inflammatory cytokines. Hence rebalance levels of these cytokines are
potential therapies to alleviate IBD [112]. As found in ELISA analysis, seven proinflammatory cytokines (GM-CSF, IFN-γ, IL-1β, IL-2, IL-6, KC/GRO, and TNF-α) were
overrepresented in DSS-treated group as shown in Fig. 10C. TNF-α is one of the most
effective proinflammatory cytokines in IBD that can directly disrupted epithelial barrier
and inducted apoptosis in epithelial cells [119]. IFN-γ is an indispensable proinflammatory
cytokine in the initiation of DSS colitis with pleiotropic functions including stimulation of
T and natural killer (NK) cells and modulation chemokines [120]. IL-1β signals are
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required for the development of severe inflammation in both T cell-mediated and T cellindependent colitis [121]. Over expression of IL-6 can activate the anti-apoptotic genes
Bcl-xl, leading to the expansion of T-cell, which further induce the chronic intestinal
inflammation [122]. In line with previous studies, dietary resveratrol significantly
mitigated the overexpression of TNF-α, IFN-γ, IL-1β and IL-6 in DSS-treated mice (Fig.
13C) [1, 103, 123]. The precise role of GM-CSF in the pathogenesis of IBD is contradictory
now. It is believed that production of GM-CSF is related to a delayed neutrophil apoptosis,
which contributes to the tissue injury in IBD and an increased secretion of GM-CSF has
been found in mucosal lesions of mouse model and IBD patients [124, 125]. In contrast,
some studies indicate that GM-CSF plays a protective role in intestinal infection and
benefits in overcoming bacteria invasion [27]. Here we for the first-time report that dietary
resveratrol down-regulated the enhanced GM-CSF production in DSS-induced colitis mice
model (Fig. 13C). KC/GRO is a CXC chemokine also known as chemokine (C-X-C motif)
ligand 1 (CXCL1). During inflammation, it is involved in neutrophil activation and
recruitment [126]. It has been reported that the level of CXCL1 in serum is highly
correlated with the grade of disease in the IBD patients [126]. We firstly indicate here that
dietary resveratrol inhibited DSS-induced colitis through CXCL1-mediated pathways (Fig.
13C). IL-2 is discovered as a key cytokine that supports the proliferation and differentiation
of regulatory T cells. Subsequently, aberrant expression of IL-2 promotes the imbalance
between effector T cells and regulatory T cells, which leads to multi-organ autoimmune
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disease and inflammation [127]. We firstly revealed the expanded expression of IL-2 in
DSS-induced colitis mice model. More meaningful our result showed that dietary
resveratrol down-regulated IL-2 to the level of control group in DSS-treated mice (Fig.
13C). In addition, we also evaluated the expression levels of two anti-inflammatory
cytokines (IL-4 and IL-10) in colonic mucosa. IL-10 exerts its anti-inflammatory property
by inhibiting pro-inflammatory cytokines such as IL-1, IL-6, IL-12 and TNF-α as well as
chemokines [128]. In our study the expression changes of IL-10 showed similar pattern
with other pro-inflammatory cytokines - augmented in DSS group and cut down in DSSresveratrol group (Fig. 13C). This result is contradictory with previous study [129]. We
speculated the possible cause behind this finding is stressful reaction to extremely severe
inflammation (overexpress of IL-10 to overcome expansion of seven proinflammatory
cytokines) [130]. Concentration of IL-4 monitored as well. No significant differences
existed among groups (data not shown). Above results suggested the potent antiinflammatory effects of dietary resveratrol via inhibition of pro-inflammatory mediator’s
production.

The impact of dietary resveratrol on relative abundance of the predominant taxa in all
samples was evaluated based on the following criteria: phylum, class, order, family, and
genus. In accordance with previous research, the dominant bacterial phyla in healthy adults
are Firmicutes, Bacteroidetes, and Actinobacteria, normally with lower abundances of
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Verrucomicrobia and Proteobacteria [131]. Consistently, we found that Firmicutes,
Bacteroidetes and Actinobacteria accounted more than 95% of the whole gut microbial
composition in control group. While in DSS group, these three phyla only occupied 56.5%.
At the meantime, Proteobacteria and Verrucomicrobia increased to 41.4% of the gut
microbial composition in DSS group (Fig. 14C). At the genus level, a lifted proliferation
of Lactobacillus and Bifidobacterium was observed in resveratrol group, which suggested
that dietary resveratrol could promote the enrichment of probiotics (Fig. 14D-14F). In fact,
several studies have demonstrated a protective effect of Lactobacillus and Bifidobacterium
in DSS-induced colitis, impacting multiply parameters like proinflammatory cytokines and
oxidative damage [132]. More meaningfully, we found that resveratrol successfully
restored the frequencies of Bifidobacterim to control level in DSS-treated mice (Fig. 14D14F). From other side, dietary resveratrol also improved the dysbiosis of some potential
pathogens induced by the colitis, such as Akkermansia, Biliphila and Sutterella (Fig. 14D14F). Akkermansia is a Gram-negative mucin-degrading bacterium and the only member
of Verrucomicrobia phylum identified to date [133]. Seregin et al. concluded that
Akkermansia acted as a pathobiont to promote colitis in a genetically susceptible host under
the regulation of nod-like receptor 6 (NLRP6) [134]. Moreover, the enrichment of
Akkermansia has been reported in faeces of mice with DSS-induced colitis and patients
suffering from colorectal cancer [135, 136]. Biliphila belonging to phylum of
Proteobacteria is sulfate-reducing bacteria associated with IBD and appendicitis [137].
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Sutterella Wadsworthensis (belonging to genus of Sutterella and phylum of Proteobacteria)
has been suggested could induce inflammation cascades by occupy the mucus layer [138].
Our results revealed that dietary resveratrol strikingly reversed these unfavorable changes
in DSS-treated mice (Fig. 14D-14F). We also observed significantly differences of Dorea
(belonging to phylum of Firmicutes)) richness among different groups (Fig. 14F). Limited
researches on Dorea have been published. One clinical study indicated that Dorea
represented lower level in IBD patients, suggesting Dorea may act as a probiotic [139]. To
our best knowledge, this is the first time demonstrate that dietary resveratrol alleviated
microbial community perturbations by selectively restoring the proliferation of probiotics
and blunting the expansion of potential pathogens in DSS-induced colitis mice model.
These findings could suggest a possible prebiotic effect of resveratrol on the microbiota,
which may influence the host metabolism. Nevertheless, the mechanism of how resveratrol
affects the gut microbiota remains an important field of future research.

To better understanding the relationship between dietary resveratrol, inflammatory
cytokines and gut microbiota, we analyzed the correlation between cytokines and gut
microbiota. As observed in Fig. 15, pro-inflammatory cytokines (GM-CSF, IFN-γ, IL-1β,
IL-2, IL-6, KC/GRO, and TNF-α) were significantly positively correlated with potential
pathogenic gut microbiome (Akkermansia, Bilophila, Parabacteroides, Ruminococcus, and
Sutterella) and negatively correlated with probiotics (Bifidobacterium, Lactobacillus and
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Roseburia). Positive correlation between TNF-α with family Ruminococcacease and genus
Parabacteroides,

and

negative

correlation

with

family

Rikenellaceae,

family

Lachnospiracease and genus Lactobacillus were reported in previous studies [140, 141],
suggesting a crucial role of gut microbiota in TNF-α production [142]. The protective effect
of Lactobacillus and Bifidobacterium in DSS-induced colitis by modulating
proinflammatory cytokines has been discussed [132]. Accordingly, we demonstrated their
positive correlation with anti-inflammatory cytokine IL-4 and negative correlation with
potential pathogens (Fig. 15). Here we for the first time systematically report the complex
correlation between inflammation-associated cytokines and gut microbiota abundance in
DSS-induced colitis model. These results offer a clue to further investigate the causality
between these two events and illustrate the pathogenesis of IBD.

In conclusion, our results reinforced the important role of dietary resveratrol (2
mg/kg/day) as a multitargeted anti-inflammatory compound. The effects of resveratrol on
DSS-induced colitis and the gut microbiota were clearly revealed, and the complex
correlation between inflammatory cytokines and gut microbiota was systematically
displayed. However, whether the anti-inflammatory effects observed are due exclusively
to the direct resveratrol action or it is also mediated by the gut microbiota deserves further
investigation.
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CHAPTER 5

EFFECTS OF ALTERED GUT MICROBIOTA ON BIOTRANSFORMATION OF
RESVERATROL

5.1 Introduction

Resveratrol is a phytochemical that can be found in variety of foods and plants, such
as grapes, peanuts, pistachios, berries, and Japanese knotweed [143]. Resveratrol is
marketed by many nutritional supplement companies due to its wide range of health
benefits functions. Resveratrol decreased trimethylamine-N-Oxide levels and increased
hepatic bile acid neosynthesis, thus potentially attenuated atherosclerosis [115]. Fat storage
was lowered by resveratrol in obesity mice [144]. Resveratrol also exhibited comparable
beneficial effects with calorie restriction diet on extending the lifespan of mice and
Caenorhabditis elegans [145, 146]. In addition, resveratrol may act as an antiinflammatory and anti-cancer agent [82].

Though vast amount of data has become available, the biological effects of resveratrol
and their underlying mechanism are not fully understood yet. This may partially due to the
knowledge gap of the metabolic fate of resveratrol. Fully elucidating he metabolic route of
resveratrol is crucial, because the derived metabolites may have significantly different
chemical, which will lead to different biological characters. Numerous studies have
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provided consistent information about the conjugation of resveratrol via intestinal and
hepatic metabolism [5, 70, 93]. Our recent studies emphasized the critical role of microbial
metabolites of resveratrol: dihydro-resveratrol (DHR) and lunularin (LUN), not only
because of their high concentration, but also their stronger chemopreventive effects on antiinflammation and anti-proliferation (unpublished data) at achieved tissue levels. These
innovative results driven our attentions from hepatic and small intestinal to microbial
biotransformation of resveratrol.

The microbial biotransformation of dietary polyphenols, including ring fission,
reduction, demethylation, hydrolyzation glycosides, and dihydroxylation, has been well
described [13, 14]. On the one hand, significantly interindividual differences exist in gut
microbial composition, which may lead to different microbial transformation patterns of
polyphenols. As in the case of production of either equol or O-demethylangolensin and
dihydrodaidzein from daidzein [15]. On the other hand, gut microbiota composition could
be dramatically altered in various diseases [16]. Previous study indicated that gut
microbiota diversity and balance between pathogens and probiotic were significantly
disturbed in DSS-induced colitic mice (unpublished data).

Given these complex situations, the first step of our current study was to prove that
gut microbiota was necessary in the production of DHR and LUN by using antibiotic
treated mice. Then a human study was performed to elucidate the different interindividual
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routes of resveratrol transformation by gut microbiota. Lastly, we identified, quantified,
and compared the distribution of DHR and LUN in DSS-treated colitic mice and healthy
mice, which had vital implications in biological activities of resveratrol. Overall, our
current study for the first time systematically discussed the effects of altered gut microbiota
on the biotransformation of resveratrol and its important implications in biological
activities of resveratrol, which should be taken into account during investigation of healthpromoting effects of this polyphenol.

5.2 Materials and Methods

5.2.1 Materials

RES (>99% purity) was purchased from Quality Phytochemicals (Edison, NJ, USA).
Pinostilbene (PIN) (>98% purity) and DHR (>98% purity) were obtained from Yuanye
Bio-Technology Co., Ltd (Shanghai, China). LUN (>98% purity) was purchased from
Aikon Biopharma LLC (Nanjing, China). Sulfatase (type H-1, from Helix pomatia,
containing sulfatase and β-glucuronidase) was obtained from Sigma-Aldrich (St. Louis,
MO, USA). Acetonitrile (ACN), methanol (MeOH), acetic acid, and ethyl acetate were
purchased from Fisher Scientific (Fairlawn, NJ, USA). All these solvents are HPLC grade.

5.2.2 Animals models, diets and treatments

75

The Institutional Animal Care and Use Committee, University of MassachusettsAmherst approved all animal experiments performed. Ten male CD-1 mice (6-week old)
were obtained from Charles River Laboratory (Wilmington, MA, USA). Mice were housed
individually in a cage and cage bedding was changed two times per day. After one week
of diet acclimation, all mice receive resveratrol enriched diet, which contained 0.025%
(w/w) RES in standard AIN93G diet for five days. From day 6, all mice continuously
received resveratrol enriched diet but drink antibiotic water (AB), which contained broadspectrum antibiotics (ampicillin and neomycin) [147]. At the day 10, all mice were
sacrificed with CO2 asphyxiation. The urine and fecal samples were collected everyday
with Labsand (Braintree, MA) for further HPLC-MS analysis.

Twenty male CD-1 mice (6-week old) were obtained from Charles River Laboratory
(Wilmington, MA, USA). After one week of diet acclimation, mice were randomly divided
into two groups. Ten mice in RES group fed standard AIN93G diet containing 0.025%
(w/w) of RES and normal drinking water. The other ten mice in DSS RES group fed
standard AIN93G diet enriched with 0.025% (w/w) of RES and received 1.5% DSS water
(wt/v, dextran sulfate sodium salt) (International Lab, Chicago, IL). 1.5% DSS was
administered in the drinking tap sterilized water ad libitum for 4 days followed by 7 days
of pure water for recovery, and this cycle was repeated four times. At the end of the fourth
cycle of DSS treatment, all mice were sacrificed with CO2 asphyxiation. Heart, liver, spleen,
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lung, kidney, brain, stomach, small intestine (transversely cut equally into four parts),
cecum, colon and bile were collected and stored at -80°C for further analysis. Blood
samples were centrifuged at 3 000g for 15 mins at 4°C to collect serum.

5.2.3 Sample preparation

Serum, bile and urine samples were extracted according to Menet et al. [93]. Briefly,
aliquots of samples were vortex-mixed with ten volume of acidified (2.5% acetic acid)
ACN and stood at ice for 20 min to precipitate the protein. After centrifugation (14000 rpm,
10min, 4°C), the supernatant was evaporated to dryness using a Speed Vac Concentrator
(Savant Thermo Fisher Scientific Inc., Agawam, MA). Tissue and fecal samples were
prepared according to Juan et al. with modifications [67]. Briefly, aliquots of tissues were
homogenized with 10 volume of MeOH/water/acetic acid (80:20:2.5) solution using a Bead
Ruptor Homogenizer (Omni International, Kennesaw, GA). The homogenates were then
centrifuged at 14000 rpm for 5 min. Specially for kidney samples, the homogenate was
sonicated for 20 min before centrifugation. The residues were extracted one more time and
combined methanolic layers were evaporated to dryness under vacuum. All sulfated and
glucuronide metabolites were measured by enzymatic hydrolysis of the processed samples
with β-glucuronidase and sulfatase as reference described [74]. The internal standard PIN
(5 μmol/L) was routinely used in all the samples. The dried extractions were reconstituted
in 50 μL 50% MeOH for further analysis.
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5.2.4 Sample analysis with HPLC-MS

The concentration of RES and its metabolites were quantified by using the Shimadzu
Model 2020 HPLC-MS (Shimadzu, Kyoto). The metabolites were eluted with a Zorbax
SB-Aq C18 column (Agilent Technologies, Santa Clara, CA, USA) at flow rate of 0.6
mL/min. Mobile phase A was 5% acetonitrile/water, mobile phase B was 100% acetonitrile.
Gradient elution started at 15% solvent B, linear gradient from 15 to 70% solvent B over
18 min, held at 70% B for 3 min, then followed by washing and reconditioning the column.
The Mass-spectra conditions were optimized at negative electrospray ionization mode, as
follows: Heat block temperature 400°C, desolvation line temperature 250°C, interface
voltage -3.5 kv, and drying gas flow 15 L/min. Data acquisition and processing were
accomplished using Labsolutions Software (Shimadzu).

5.2.5 Cell viability assay, colony formation assay, nitric oxide assay and anti-oxidant assay

We adopted various cell models to investigate the multiple biological activities of RES
and its metabolites at achieved colon tissue levels, including anti-proliferation of cancer
cells, anti-inflammation, anti-oxidant and anti-colony formation. All cells were purchased
from American Type Cell Collection (ATCC, Manassa, VA, USA). HT-29 and HCT-116
were applied to MTT and colony formation assays as described previously to explore the
anti-proliferative effects [95-97]. Nitric oxide assay (anti-inflammation) were performed
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according to Guo et al. in RAW264.7 macrophage model [95, 96]. Caco-2 cells based antioxidant assay consulted with previous reference [148].

5.2.6 Statistical analysis

All data were expression as Mean ± standard deviation (SD). The statistical
significance was assessed by one-way ANOVA with post hoc Tukey HSD test. P value <
0.05 was considered as statistically significant.

5.3 Results and discussion

5.3.1 DHR, LUN and their conjugates absent in antibiotic treated mice

Walle et al identified DHR as a major metabolite of resveratrol, that was likely
produced by the intestinal microbiota for the first time [5]. Later, Slackia equolifaciens,
Adlercreutzia equolifaciens, and Eggerthella lenta ATCC 43055 were identified as DHR
producers [74, 75]. LUN was identified as a microbial metabolite of resveratrol in an in
vitro fermentation study by Bode el al firstly, though the responsible producer was not
identified [74]. These results indicated that the production of DHR and LUN was
associated with gut microbiota, but still could not exclude the potential involvement of
enzymes abundant in liver, kidney and upper gastrointestinal tract, like CYP450 [149].
Especially, DHR, LUN and their conjugates were detected in the stomach content and
tissue in mice (unpublished data). Therefore, broad-spectrum antibiotic was used to wash
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out the gut microbiota in mice in our study. The metabolites of resveratrol were compared
before and after antibiotic treatments. Previous studies demonstrated that antibiotics
treatments significantly decreased diversity, richness and evenness of the fecal microbiota
[150]. Ampicillin and Neomycin were chosen due to their poor absorption in small intestine,
which resulted in better target to the commensal microbes [151].

As shown in Fig. 16A, 16C, all mice could metabolize RES to DHR, while only three
mice could produce DHR before antibiotic treatment. LUN was a minor metabolite in mice
#2, which only occupied for 4.59% of the total metabolites. While DHR and its conjugates
account 84.75% of the metabolites in #2 mice (Fig. 16C). In mice #6 and #8, LUN and its
conjugates accounted over 50% of the metabolites in the urine. These results could attribute
to the interindividual differences in gut microbiota. In other five mice, RES-conjugates,
DHR, and DHR-conjugates were major metabolites of RES. Unmetabolized RES taken up
to 17.9% of the total derivates (Fig. 16C). These results were consistent with our previous
studies.

Strikingly, DHR, LUN and their conjugates were totally disappeared after five days
antibiotic treatment as shown in Fig. 16B. These results for the first time fully demonstrated
that DHR and LUN are strictly microbial metabolites of resveratrol. The appearance of
DHR, LUN and their conjugates in the upper GIT and tissues were due to the reabsorption
of DHR and LUN in large intestine. These findings provided fundamental information in
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the metabolic pathway of resveratrol after oral consumption in human.

Fig. 16 Metabolites of resveratrol before and after antibiotic treatment in the urine. (A)
Metabolites of resveratrol in the urine before antibiotic treatment. (B) Metabolites of
resveratrol in the urine after antibiotic treatment. (C) Relative abundance of resveratrol
metabolites in the urine before antibiotic treatment.
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5.3.2 Biotransformation of RES in DSS-induced colitis mice

We had observed that the anti-inflammatory and anti-proliferative effects of DHR and
LUN were significantly stronger than RES at the observed colon tissues levels
(unpublished data). Dramatically gut microbiota alteration was also announced in our
previous research (unpublished data). Taken all these observations together, we
hypothesized that altered gut microbiota in DSS-induced colitis mice would change the
biotransformation of RES in large intestine and further impact its biological activities.

The concentrations of RES, DHR, LUN and their conjugates in the colon and cecum
tissues were compared between heathy mice and DSS-treated colitis mice (Fig. 17). Most
strikingly, LUN and its conjugates were totally deracinated in the cecum and colon tissues
in the DSS-treated mice (Fig. 17). It was also noteworthy that the concentrations of RES
were 34.39 and 6.49 nmol/g, respectively in the cecum and colon tissues in the DSS-treated
mice, which were much higher than those in the healthy mice (cecum: 4.32 nmol/g;
colon:1.32 nmol/g). We speculated that the disappeared LUN and increased RES in the
large intestine in colitic mice may resulted in different biological effects of RES at the site
of function. The conjugated RES and DHR in the cecum were higher in colitic mice
compared with healthy mice, which indicated the weaker deconjugation capacity of gut
microbiota in the cecum in the colitic mice (Fig. 17).
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Fig. 17 Concentration of RES metabolites in the cecum and colon tissues in the healthy
mice (A) and colitic mice (B).

To further confirm the distinguished metabolism patterns in colitic mice vs healthy
mice. The distribution of RES metabolites in the bile, liver, kidney, and serum were
analyzed. Generally, LUN and its conjugation remained unshown in the colitic mice (Fig.
18), which further supported that LUN was produced by gut microbiota. The
concentrations of all metabolites were lower in colitic mice compared with healthy mice,
which may due to the lower food intake and/or impaired gastrointestinal absorption
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function in colitic mice [152, 153].

DHR and LUN were reabsorbed from large intestine and concentrated in the bile. We
consistently observed the absence of LUN and its conjugates in the bile in colitic mice (Fig.
18). In the bile, the concentration of RES-M was as high as 335.23 μmol/L, which was
much higher than DHR-M (165.80 μmol/L) and LUN-M (174.66 μmol/L) in healthy mice.
Among these, quiet amount of unmetabolized RES (10.23 μmol/L), DHR (49.69 μmol/L),
and LUN (52.07 μmol/L) were observed in healthy mice (Fig. 20). While, in the colitic
mice RES-M was apparently lower than DHR-M, which may due to the lower food intake
and/or impaired small and large intestinal function in colitic mice [152, 153]. The
concentrated DHR and LUN further entered in to the enterohepatic circulation and
underwent extensive phase II metabolism.

In the serum, no free formed metabolites were detected in both colitic mice and
healthy mice. Patel and Brown fed mice with RES-3-O-sulfate and RES-4’-O-sulfate
proved that conjugated metabolites served as an intracellular pool in the body from which
RES could be regenerated locally, this could be the same case for DHR and LUN [83].
Thus, in the liver and kidney, free formed DHR and LUN were observed. Especially, in
the kidney free-formed metabolites accounted 67.36% of the total metabolites in healthy
mice. Our previous study indicated that at the achieved tissue levels, free formed DHR and
LUN exhibited stronger anti-cancer effects than RES alone in the renal carcinoma cell lines.
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The lower concentration of free-formed RES and DHR in the kidney in colitic mice may
compromised these heathy benefits.

Fig. 18 The distribution of RES metabolites in the bile, liver, kidney, and serum in the
colitic mice vs healthy mice.

5.3.4 Stronger chemopreventative effects of RES metabolites at concentrations equivalent
to that found in the colon tissues in the colitic mice vs healthy mice

we found that DHR, LUN and their combination exerted much stronger chemopreventive and anti-inflammatory effects in the colonic tissues, at their concentrations
achieved in the tissues, suggesting that DHR and LUN may greatly contribute to the
chemopreventive properties elicited by RES in the colon. Meanwhile, above data

indicated that LUN and its metabolites were disappeared in the DSS-treated mice
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due to the altered gut microbiota. These preliminary data guaranteed the further
investigations on chemopreventative effects of RES metabolites at the tissue
relevant levels in the colitic mice. To establish the protective effects of RES and its
metabolites in a physiologically relevant manner, we deliberately used the concentrations
measured in the colonic tissues to determine their bioactivities.

To establish the anti-colitis and anti-colon cancer effects of DHR and LUN in a
physiologically relevant manner, we determined their inhibitory effects on two widely used
human colon cancer cell lines (HCT-116 and HT-29) at the concentrations found in the
mouse colonic tissues. Treatment of 1× stood for concentrations measured in the colonic
tissue, that was combinations of 1.32 nmol/g of RES, 37.96 nmol/g of DHR and 38.89
nmol/g of LUN in the healthy mice or 22.07 nmol/g of RES and 41.53 nmol/g of DHR in
the DSS-treated mice (Fig. 19A). Generally, RES metabolites at the concentrations equal
to that found in the colitic mice exhibited stronger anti-inflammation and anti-proliferation
abilities than that found in the healthy mice (Fig. 19 B-D), which explained the anti-colitis
effects of resveratrol supplementation in DSS-induced colitis mice (unpublished data).

LPS-stimulated RAW 264.7 macrophages were used to determine the antiinflammatory potency of RES metabolites. RES metabolites at concentrations equivalent
to that in the healthy mice showed a tendency to suppress the production of NO (an
important inflammatory mediator). While, the inhibitory effects of RES metabolites at
86

Fig. 19 Chemopreventative effects of RES metabolites in the DSS-treated mice vs healthy
mice. (A) Concentrations of RES metabolites in the colonic tissue in healthy mice vs colitic
mice. (B) Percentage of inhibition on NO production by RES metabolites in LPSstimulated RAW 264.7 cells. (C) Growth inhibitory effects of RES metabolites on HCT116 cancer cell line. (D) Anti-proliferative effects of RES metabolites on HT-29 cancer cell
line. Data presented as mean ± SD (n=3). Statistical differences were indicated as: *, P <
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0 .05; **, P < 0.01.

concentrations relevant to that in the colitic mice increased by 12.2, 9.59, 11.44, and 14.08%
at 0.5, 0.75, 1 and 1.5×, respectively, compared with healthy mice (P < 0.05) (Fig. 19).

In addition, HCT-116 and HT-29 cell lines were subjected to a series of
treatments. Generally, HCT-116 cell line was more vulnerable than HT-29 upon the
treatments of RES metabolites. For example, RES metabolites at the healthy mice
relevant levels of 1× suppressed 16.95 and 1.86 % of the growth of HCT-116 cell lines
vs HT-29 cell lines (Fig. 19C, 19D). While at the concentrations equal to that found in
tDSS-treated mice in the colonic tissue, 26.80 and 13.83% of HCT-116 and HT-29 cells
were suppressed (Fig. 19C, 19D). The stronger chemopreventative effects of RES
metabolites at concentrations relevant to that found in the colitic mice than that observed
in healthy mice may due to the higher concentration of RES in the colitic mice. Our
previous study demonstrated that RES exhibited stronger chemopreventative effects
than DHR and LUN at the same concentrations (supplementary figures Fig. S3). These
results provided a vital scientific basis for understanding the chemopreventative
mechanisms of RES from the perspective of biotransformation of RES by gut microbiota.

5.4 Conclusion

In current study, we systematically and deeply discussed the complex relations
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among gut microbiota, RES biotransformation and biological activities of RES. The study
for the first time fully demonstrated that gut microbiota mediated metabolism was the only
way to bio-transformed RES to DHR and LUN in vivo. Our results further indicated the
important role of gut microbiota in the pronounced interindividual variations in
biotransformation of RES. RES in LUN non-producers may have higher bioavailability
due to the lower urine excretion. We also firstly reported that in the colitic mice LUN and
its conjugates were extinct due to the altered gut microbiota compositions and structures.
More meaningfully, we found that RES metabolites at the concentrations equivalent to that
observed in the colonic tissues in colitic mice exhibited significantly stronger
chemopreventative effects than that observed in the healthy mice. These results suggested
that absence of LUN may resulted in stronger biological activities of RES. Overall, our
finding provided comprehensive scientific knowledge on the interactions between gut
microbiota and RES metabolism, and its implications in the biological activities of RES.
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CHAPTER 6

CONCLUDING REMARKS

Over 1 million residents in the USA are estimated to be suffering from
inflammatory bowel disease, which include Crohn’s disease and ulcerative colitis. One of
the most important and devastating complications of long-term IBD is colorectal cancer
development. Epidemiological evidences suggested that diet enriched with fruits and
vegetables were strongly associated with lower cancer occurrence. Resveratrol has
attracted much scientific attentions because of its potentially beneficial effects on
numerous disorders, including colon inflammation and colon cancer.

The present dissertation for the first time systemically determined the
biotransformation of RES in mice, with focuses on its metabolic fate in the GIT. Our results
demonstrated that DHR, LUN and their corresponding conjugates were dominated
metabolites of RES after sustained oral consumption of RES, rather than RES-sulfates and
RES-glucuronides. More importantly, we found that DHR, LUN and their combination
exerted much stronger chemo-preventive and anti-inflammatory effects in the renal and
colonic tissues, at their concentrations achieved in these tissues, suggesting that DHR and
LUN may greatly contribute to the chemopreventive properties elicited by RES in the
kidney and colon.
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Accumulating evidence indicated that gut microbiota plays important roles in the
pathogenesis of colitis, and microbiota composition could be modulated by dietary
components. Herein, we determined the effects of resveratrol on gut microbiota and their
implication in anti-colonic inflammation in mice with colitis induced by dextran sodium
sulfate (DSS). Our results reinforce the protective effects of resveratrol in intestinal
inflammation by alleviating the body weight loss, reducing the disease activity index,
attenuating tissue damage and modulating inflammatory cytokines. Moreover, dietary
resveratrol restored the microbial richness and evenness in DSS-treated mice.

The complex relations among gut microbiota, RES biotransformation and
biological activities of RES were deeply discussed. Our results demonstrated that gut
microbiota mediated metabolism was the only way to bio-transformed RES to DHR and
LUN in vivo. Gut microbiota played an important role in the pronounced interindividual
variations in biotransformation of RES. RES in LUN non-producers may have higher
bioavailability due to the lower urine excretion. We also firstly reported here that in the
colitic mice LUN and its conjugates were extinct due to the altered gut microbiota
compositions and structures. More meaningfully, we found that RES metabolites at the
concentrations equivalent to that observed in the colonic tissues in colitic mice exhibited
significantly stronger chemopreventative effects than that observed in the healthy mice.
These results suggested that absence of LUN may resulted in stronger biological activities
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of RES. Overall, the findings presented in this dissertation provided a solid scientific basis
for understanding the chemopreventive mechanisms of RES from the perspective of
biotransformation and are of great value for future research on RES in prevention and
treatment of colonic diseases in humans.
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APPENDIX

THE FIGURES

Fig. 20 Mass spectra of RES metabolites at negative mode.
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Fig. 21 Anti-proliferative effects of RES, DHR and LUN on normal human colon CCD18Co cell lines.

Fig. 22 Percentage of inhibition on NO production by RES, DHR, LUN in LPS-stimulated
RAW 264.7 cells at concentrations of 10 μM, 20 μM, and 40 μM.
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